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NY-ESO-1 is an important cancer immunotherapy target that has proven to be 
impossible to produce in soluble form in Escherichia coli. Targeting this protein for 
secretion in Pichia pastoris results in its retention within the cell. By utilizing the 
downstream purification methods developed for E. coli inclusion bodies, we are able 
to purify NY-ESO-1 aggregates from P. pastoris lysate.  The his-tag is cleaved off by 
unknown cellular processes preventing the purification of NY-ESO-1 by metal affinity 
chromatography. Removal of one C-terminal arginine residue destroys a potential 
Kex2 protease site and results in the retention of the his-tag.   
The A33 scFv protein is efficiently secreted by P. pastoris to the culture 
supernantant at levels approaching 4 g/L.  An attempt was made to further enhance 
this yield by overexpressing two proteins involved in the last stage of protein 
secretion, the Saccharomyces cerevisae SNARE proteins Sso1 and Snc2. 
Overexpression of Snc2 or Sso1 have no impact on cell growth, and Sso1 
cooverexpression leads to the enhancement of A33 scFv yields by up to 81% in high 
cell density fermentor cultures.  Snc2 cooverexpression has no effect, and 
cooverexpression of either of these proteins with A33 scFv and the ER resident 
chaperone BiP led to a defect in cell growth and a decrease in A33 scFv yield.   
There is a growing body of evidence showing that certain proteins in a wide 
range of cell types are secreted by means not involving the classical secretory 
 pathway. One of these proteins is enolase, and it has been shown in S. cerevisae to be 
capable of driving the secretion of enolase-GFP and enolase-invertase fusions to the 
extracellular space independent of the ER and golgi.  A fusion protein between enolase 
and the cancer differentiation antigen MelanA was generated.  In shake flask cultures, 
fusion protein could be detected in the supernatant by immunoblot, and additional 
protein was able to be liberated from the cell wall by gentle washing with buffer 
containing 2-mercaptoethanol. Fermentor cultures, however, accumulated very little 
fusion protein in the culture supernatant, but significant degradation could be detected 
when blotting with an anti-enolase polyclonal antibody.  
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Introduction 
Expression of full length recombinant proteins for therapeutic or industrial uses in 
microbial expression systems is becoming increasingly popular as more useful 
proteins are isolated and characterized.  As larger and increasingly complex proteins 
are desired, more sophisticated expression platforms are also needed to address the 
specific challenges associated with their production.  Attention must also be paid to 
how the specific choice of expression platform and its treatment will impact the 
eventual downstream purification.   
 
Escherichia coli is often one of the first choices for recombinant protein expression 
because of its facile and well known genetics, high growth rate, and ability to express 
large quantities of protein rapidly.  Often, bacteria are incapable of properly folding 
and modifying many proteins isolated from higher eukaryotes.  As a result the protein 
is incorporated into large insoluble masses that collect at the poles of the cell called 
inclusion bodies (Villaverde and Mar Carrió 2003).  While inclusion bodies are highly 
enriched with the protein of interest and can be isolated from the host cell 
contaminants by centrifugation or filtration, the protein is often useless for its intended 
purpose and will require refolding.  Coupling this with the need to use high 
concentrations of denaturants and detergents to keep the misfolded protein in solution 
during purification, downstream processing can often be difficult and expensive when 
using bacterial expression systems (Marston 1986). 
 
At the other end of the spectrum lies the expression of recombinant proteins in 
mammalian cell lines.  Immortal cell lines such as Chinese Hamster Ovary (CHO) and 
Human Embryonic Kidney (HEK) have been developed and used for the expression of 
a number of recombinant proteins (Wurm 2004).  The main advantage with this 
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expression system is the ability of the cells to perform all of the posttranslational 
modifications that are required.  The protein is extracted from the cells ready to use 
once purified.  Genetic manipulation of these cell lines is not as simple as with 
bacteria, and growth media can be expensive and complex.  Cell density is far lower 
than that achieved with bacteria, and total growth times can be much longer.   
 
Yeast expression systems provide some of the advantages of both bacterial 
fermentation and mammalian cell culture.  Saccharomyces cerevisiae has been used 
for thousands of years in the manufacturing of bread and alcohol, and its physiology 
and genetics are very well understood.  The transformation of S. cerevisiae and related 
yeasts is simple and rapid, and fermentation media is simple and well defined.  Cell 
densities can be very high, and fermentation can be completed quickly, yielding high 
concentrations of protein.  One important difference between yeast based expression 
versus bacterial expression is in the ability of yeast to perform many post translational 
modifications, such as disulfide bond formation, glycosylation, and phosphorylation.  
Furthermore, yeast are sometimes able to secrete the target protein to the exterior of 
the cell, removing the need for cell lysis and greatly facilitating downstream 
purification.  While the post-translational modifications performed by the yeast cells 
are not always the same as performed in mammalian systems, this is often outweighed 
by the speed of growth and the far less complex and expensive growth requirements, 
particularly for proteins with a non-clinical use.   
Pichia pastoris 
The yeast Pichia pastoris was originally isolated and studied for its ability to consume 
methanol.  Phillips Petroleum was trying to develop methods to better utilize the large 
volumes of methanol they would produce as a waste product.  P. pastoris 
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fermentations on methanol were developed to produce single cell protein, intended as 
a feed additive (Cereghino and Cregg 2000).  Ultimately, the oil crisis of the late 
1970's prevented this process from being cost effective, and the program was 
canceled.  Dr. James Cregg began working with P. pastoris as an expression system 
and was the first to isolate the promoter for the alcohol oxidase gene AOX1, the first 
protein involved in the consumption of methanol. 
 
From a recombinant protein production standpoint, the AOX1 promoter is ideal 
because it is very tightly regulated in the presence of most carbon sources such as 
glycerol and glucose, but is very strongly induced upon exposure to methanol as the 
sole carbon source, when alcohol oxidase levels can reach 30% of total cellular protein 
(Cregg et al. 1989).  Alcohol oxidase is delivered to the peroxisome, and the 
peroxisomes can get very large and constitute up to 80% of the cell volume, with each 
of these full of large crystal aggregates of alcohol oxidase (Subramani 1998).  
Subsequent work showed that P. pastoris was capable of processing secretion signals 
commonly used in S. cerevisae recombinant expression systems, in particular the -
mating factor (Cregg et al. 1993).  These experiments opened the door to the use of P. 
pastoris as a recombinant expression platform, and later work expanded upon the 
library of plasmids and promoters available to researchers (Cregg et al. 2000).   
 
The mode of transformation is particularly well suited to protein expression as the 
expression cassette is incorporated into the genome through homologous 
recombination into the AOX1 promotor locus (Cregg et al. 1985).  Initial transformant 
selection can be done through auxotrophic or antibiotic resistance markers, and with 
the case of antibiotics, they need not be included in downstream media recipes as the 
cassette integration is very stable.  From a regulatory standpoint, the lack of antibiotics 
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is very beneficial, and strain characterization is simpler as the stability of plasmids 
does not have to be demonstrated.   Numerous different strains are available with a 
variety of knock-out mutations, allowing transformation with five or more different 
expression cassettes (Daly and Hearn 2005).  While the AOX1 promoter remains the 
preferred promoter, the weaker PEX8 promoter has recently been isolated and utilized 
for weaker, methanol induced expression of proteins for which the levels of expression 
using AOX1 prove detrimental to cell growth (Johnson et al. 2001).  Constitutive 
expression using the GAP promoter has also gained in popularity, as it induces to a 
lesser extent than AOX1 as well, but constitutive expression is not desirable for toxic 
proteins (Waterham et al. 1997).   
 
Selection of transformants using Zeocin or Geneticin has the added benefit of easily 
selecting for multi-copy integration events (Vassileva et al. 2001).  In a low percentage 
of transformants, the expression cassette will be integrated in multiple copies (Clare et 
al. 1991).  These transformants can grow on higher levels of antibiotic, and this 
provides a quick and easy method to screen for those transformants that may produce 
larger quantities of recombinant protein.  Hohenblum et. al. demonstrated that a strain 
with one copy of the human trypsinogen gene showed a 1.5 fold increase over a 
constitutive control, two copies led to a two fold increase, while three copies or more 
had low trypsinogen levels in the cell supernatant (Hohenblum et al. 2004).   
 
While the advantages of P. pastoris certainly argue for the increased use of this 
organism as an expression platform, the main advantage clearly lies in the secretory 
ability.  As the culture supernatant contains very few host proteins, protein purity is 
already very high with no purification steps whatsoever (Tschopp et al. 1987).  Many 
proteins arrive in the culture supernatant fully active, and it is possible that a simple 
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buffer exchange is all that is required to prepare the protein for many uses.  Coupled 
with a simple, defined medium, the act of removing the cell mass can lead to 
impressive purities with no additional steps.  Secretion can, however, be difficult to 
achieve, a trait that seems to be very protein specific.  In P. pastoris, secretion of 
gelatin has been achieved at levels of 14.8 gL
-1 
(Werten et al. 1999), and single chain 
antibody fragments (scFv) at 4 gL
-1 
(Damasceno et al. 2004) while the proteins 
MAGE-A3 and MelanA, among others, fail to be secreted at all.  If secretion is 
achieved, scale up from shake flask to high cell density fermentor cultures is typically 
straightforward, and the most difficult step is often generating a strain that produces 
any protein whatsoever (Cregg et al. 2000). 
Cancer Vaccination and Immunotherapy 
The treatment of cancer through vaccination is currently in its infancy.  The discovery 
of tumor associated antigens has led to the realization that it may be possible to coerce 
the immune system into recognizing tumors as non-self entities, resulting in their 
elimination.  Indeed, it is likely that regular immunosurveillance by the body detects 
and eliminates potentially cancerous cells all the time, preventing their growth and 
formation into tumors.  Cells that are able to escape initial immunosurveillance and 
form small tumors may enter into a period of equilibrium with the immune system, 
where the tumor growth is kept in check but is unable to be completely eradicated.  
During this time, tumor cells will continue to accumulate mutations and develop the 
ability to escape detection, and it is these cells that go on to form clinically relevant 
tumors.   
 
The continual evolution of the tumor to evade the immune system makes cancer 
vaccination a difficult endeavor.  One of the more difficult steps is the identification of 
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markers on the tumor cell which are not present, or present in very low concentrations, 
on normal tissue.  These tumor associated antigens (TAA) consist of mutated proteins 
such as p53 (Ito et al. 2007) and K-ras (Gjertsen et al. 1997), cancer testis (CT) 
antigens such as NY-ESO-1 (Wang et al. 1998) and MAGE-A1 (Traversari et al. 
1992), differentiation antigens such as MelanA (Kawakami et al. 1994) and NY-BR-1 
(Wang et al. 1998), and overexpressed proteins such as Her-2 (Fisk et al. 1995) and 
PSMA (Horiguchi et al. 2002).  These proteins are what will differentiate a tumor from 
the surrounding normal tissue.  Many vaccines consist of peptides from these proteins 
or the full length protein itself in an attempt to initiate an immune response against 
cells bearing these markers.  Other treatments target these proteins directly, such as the 
monoclonal antibody herceptin used to target Her-2 overexpressing breast cancer cells 
(Hudis 2007). 
 
 
Figure 1-1-Immunohistochemical staining of NY-ESO-1 in 
lung cancer (left) and normal testis (right).  Image from 
http://www.licr.org/D_programs/d4c1_AbCharacterization.p
hp 
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Vaccination with CT antigens has been the subject of numerous clinical trials.  NY-
ESO-1 protein has been shown to be highly expressed in a wide variety of tumor types 
(Figure 1-1), and its expression is restricted in normal tissue to testis (Chen et al. 
1997).  Since testicular tissue does not express major histocompatibility complex, NY-
ESO-1 vaccination will not target these cells.  One study vaccinated 12 patients with 
advanced, NY-ESO-1 positive metastatic disease with three overlapping NY-ESO-1 
peptides.  Of the 12 patients, seven exhibited disease stabilization that correlated with 
an anti-NY-ESO-1 immune response (Jäger et al. 2000).  Another study used to 
evaluate the safety of the full length NY-ESO-1 protein in combination with the 
adjuvant ISCOMATRIX provided evidence that the full length protein confers 
protection against relapse of fully resected melanoma.  Of 16 relapsed patients, five of 
seven received placebo, nine of 16 received NY-ESO-1 protein alone, and only two of 
19 received NY-ESO-1 with ISCOMATRIX adjuvant (Chen et al. 2004; Davis et al. 
2004).  More phase 1 and 2 clinical trials are ongoing around the world targeting a 
wide array of different tumor types to study safety, adjuvants, and vaccination 
schedules (Tabi and Man 2006).  These data provide exciting evidence that NY-ESO-1 
vaccination, with the right adjuvants, can help many cancer patients. 
P. pastoris Derived NY-ESO-1 as a Potential Skin-Testing Antigen 
One of the critical assays for evaluating the vaccines effectiveness is determining the 
specificity of any observed immune responses, and also to evaluate the presence of 
memory T-cells to the specific vaccine antigen.  One way to quickly and accurately 
measure this is through the delayed type hypersensitivity skin test (Figure 1-2). 
 
The skin test is commonly used in humans to detect previous exposure to the pathogen 
Mycobacterium tuberculosis (Vukmanovic-Stejic et al. 2006).  This test, called the 
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Mantoux test, involves the intradermal injection of tuberculin purified protein 
derivative (PPD).  Damage to epithelial cells during the injection and the introduction 
of antigen leads to the release of pro-inflammatory cytokines and activation of dermal 
dendritic cells and langerhans cells through toll-like receptors.  These cells 
phagocytose antigen and emigrate to the lymphatic system.  Here, antigen is presented 
to naïve and memory T cells, which undergo clonal expansion.  Antigen specific 
CD4+ T-cells travel to the site of injection, where they mediate effector responses such 
as macrophage activation to clear the antigen (Vukmanovic-Stejic et al. 2006).  This 
response causes induration and swelling at the site of injection that peaks at 48-72 
hours. 
 
The skin testing of cancer vaccine responses would first and foremost test for the 
presence of memory T-cells specific to the cancer vaccine protein.  This is vital to 
generating long term immunity and equilibrium between the immune system and the 
tumor.  Secondly, skin testing provides a means of evaluating the specificity of the 
immune response to the cancer protein.  NY-ESO-1 used in human clinical trials is 
derived from E. coli fermentation.  As a result, there will always be host specific 
contaminants within the vaccine preparation at low concentrations.  These can be host 
proteins, endotoxin, DNA, etc., and are able to elicit an immune response within the 
patient (Davis et al. 2004).   
 
If the same reagent used to vaccinate is used for skin testing, one cannot tell if a 
positive response is due to a reaction to the intended antigen or merely a response to a 
contaminant.  If, however, the skin test protein is generated from a different expression 
platform the resulting contaminants will inherently be different.  In this case, a 
positive response to the skin test is a good indication that the patient is mounting an 
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effective cellular response to the vaccine itself.  Neither vaccination nor skin testing 
are possible, however, without the necessary reagents.  In the case of full length 
protein based therapies, secretion of the target molecule by yeast can be an effective 
means to generate a steady, cost effective supply. 
Potential Bottlenecks to Protein Secretion 
Translocation into the Endoplasmic Reticulum 
While the capacity is present for tremendous secretion yields in P. pastoris, there are 
 
Figure 1-2-The immune response generated by a skin test antigen.  See 
text for details.  Image from Vukmanovich-Stejic et al. 2006. 
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numerous checkpoints in the secretory pathway that must be passed before a protein is 
released.  The first is the import of the target protein into the endoplasmic reticulum.  
This can be accomplished with one of two different types of secretory signals; co-
translational signal peptides or post-translational signal peptides (Rapoport 2007).  
Cotranslational signal peptides are typically composed of very hydrophobic residues 
early in the protein sequence that are recognized by the multi-subunit protein complex 
signal recognition particle, or SRP (Egea et al. 2005).  SRP in mammals is composed 
of a 7S RNA and six different proteins (Halic and Beckmann 2005).   
 
The order of events in cotranslational translocation can be seen in Figure 1-3, A.  As 
the protein sequence exits the ribosome, SRP binding to the nascent polypeptide 
 
Figure 1-3-Translocation of nascent polypeptides 
into the ER can occur either co-translationally (A) 
or post-translationally (B).  Figures were adapted 
from Rapoport 2007. 
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causes translation to stall while the SRP-ribosome-polypeptide complex moves to the 
ER membrane.  At the ER membrane, SRP interacts with the SRP receptor composed 
of two subunits, SR  and SR followed by an interaction between the ribosome and 
the translocon channel formed by Sec61  and Sec61  (Van den Berg et al. 2004).  SRP 
is released, and the hydrophobic signal peptide is bound within the translocon with its 
N-terminus remaining in the cytosol.  Translation is resumed and the protein is 
threaded into the ER lumen.  Upon completion of translocation, the hydrophobic 
stretch of the signal peptide bound within the translocon channel is cleaved by signal 
peptidase, and the protein proceeds to fold and resume its journey to the cell exterior 
(Tuteja 2005). 
 
Posttranslational signal peptides (see Figure 1-3, B), such as the S. cerevisae -mating 
factor which is in wide spread use in both S. cerevisiae and in P. pastoris, are less 
hydrophobic than their cotranslational cousins, and as a result SRP is not recruited to 
the nascent chain and translation proceeds unchecked (Ng et al. 1996).  The newly 
formed protein is fully translated into the cytoplasm, and the polypeptide chain is 
stabilized by cytosolic chaperones.  The signal peptide is bound to the translocon, and 
part of the protein is threaded through the pore (Plath and Rapoport 2000).  The 
peptide can travel in both directions through the pore, but on the lumenal side of the 
ER membrane, the chaperone BiP binds to the substrate, inhibiting its backwards 
movement (Matlack et al. 1999).  BiP is recruited to the translocon through its 
interaction with the J domain of the protein complex Sec62/63, which interacts with 
the translocon.  Interaction with the J domain lowers the binding specificity of BiP so 
that it can bind virtually any stretch of amino acids (Misselwitz et al. 1998).  Once the 
protein has been fully ratcheted into the ER, signal peptidase again cleaves the signal 
peptide and further post translational modifications can take place.  In this scenario, it 
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is vital that the protein does not fold in such a way within the cytoplasm as to obscure 
the signal peptide, else translocation will not occur.  Regardless of which route is 
chosen, once the protein is within the ER, there are still yet many checkpoints to pass 
before secretion is successful. 
Protein Folding and ER Quality Control 
Likely one of the biggest hurdles to successful secretion is the ability of the protein to 
be properly folded and modified within the endoplasmic reticulum.  Evolution has 
necessitated that cells have very strict control mechanisms to prevent improperly 
folded protein from traveling to a cellular compartment or cell exterior where its 
incorrect folding may elicit a harmful activity.  Numerous chaperones are present in 
the ER at high concentrations to enable this folding to occur.  One of the primary 
chaperones is BiP.  BiP is recruited to the translocon where it actively binds 
polypeptide chains as they are threaded through the pore (Brodsky et al. 1995).  In this 
fashion it prevents premature folding and aggregation until the entire chain is present.  
Through a cycle of binding and releasing from hydrophobic stretches, it acts to allow 
the protein to fold slowly and correctly.  Other chaperones assist in certain post-
translational modifications, in particular protein disulfide isomerase (PDI) which 
assists in the correct formation of disulfide bonds in the tertiary structure (Freedman et 
al. 1994).   
 
If proteins are unable to fold successfully, the cell initiates an unfolded protein 
response (UPR) (Figure 1-4).  The unfolded protein response has three goals (Görlach 
et al. 2006).  The first is to reduce the amount of protein entering the ER, while the 
second is to enhance the ability of the ER to effectively process the unfolded protein 
backlog.  The third process is initiated when the first two are unable to successfully 
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rectify the unfolded protein situation, and the result is cell death (Ron and Walter 
2007).  These processes are put in motion when ER membrane proteins sense the 
presence of unfolded proteins.  The proteins IRE1 and PERK contain ER lumen 
domains that have been shown to bind the chaperone BiP.  BiP maintains these 
proteins in their monomeric state.  As unfolded protein accumulates, BiP is titrated 
away from IRE1 and PERK in an effort to complete proper folding.  The titration of 
BiP leads to the production of IRE1/IRE1 and PERK/PERK dimers (Harding et al. 
2003).  Dimerization results in the phosphorylation of each protein, which in turn 
leads to the activation of pathways designed to rectify the ER stress.  Dimerization of 
PERK leads to the phosphorylation of eukaryotic translation initiation factor-2 
(eIF2a), which causes it to be locked in its inactive GDP bound form (Harding et al. 
1999).  The decreased amount of active eIF2a lowers the level of translation in the 
cell, decreasing the amount of new protein being introduced into the already stressed 
ER.  eIF2a phosphorylation also leads to the upregulation of genes involved in the 
unfolded protein response, such as chaperones (Harding et al. 2003).  
 
IRE1 functions in much the same way as PERK, however its phosphorylation leads to 
the activation of an endoribonuclease activity on the cytoplasmic tail of the protein.  
This activity removes an intron from the yeast mRNA HAC1 (XBP1 in mammals).  
The processed HAC1 mRNA is translated and this protein is a transcription factor that 
activates UPR genes (Cox and Walter 1996).  This response can also be seen during 
high levels of protein overexpression commonly seen in recombinant protein 
manufacturing.  Terminally misfolded proteins are eventually tagged with ubiquitin 
and translocated out of the ER, where they are then degraded by cytoplasmic proteases 
and the proteasome, which are also upregulated during the UPR. 
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A third mechanism for initiating the UPR is through the protein activating 
transcription factor 6 (ATF6) (Haze et al. 1999).  ATF6 is a transmembrane protein 
that is retained in the ER through its interaction with BiP (Shen et al. 2002).  Upon 
titration of BiP away from ATF6 due to unfolded protein accumulation, ATF6 traffics 
to the golgi where it is cleaved by the golgi resident proteases site 1 protease and site 2 
protease.  These cleavage events lead to the release of the cytosolic effector portion of 
ATF6 which traffics to the nucleus to upregulate UPR target genes (Ye et al. 2000).   
 
Protein folding, especially in recombinant production strains, is a major bottleneck to 
successful protein secretion.  Overexpression of BiP in P. pastoris has been shown to 
enhance the secretory yield of A33 scFv (Damasceno et al. 2007) and trypsinogen 
 
Figure 1-4-An overview of the unfolded protein response pathways.  
Figure adapted from Görlach et al. 2006. 
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(Hohenblum et al. 2004), while overexpression of protein disulfide isomerase (PDI) in 
S. cerevisae results in enhanced levels of human platelet derived growth factor B 
homodimer and Schizosaccharomyces pombe acid phosphatase (Robinson et al. 1994).  
This is clearly an important area to optimize when trying to maximize secretory yields 
in industrial protein production. 
ER Exit and Golgi Processing 
Once a protein is folded correctly, the next checkpoint it must bypass is exit from the 
ER.  This phenomenon is well studied in S. cerevisae, and involves COPII coated 
vesicles (Figure 1-5).  Transmembrane proteins destined for the plasma membrane or 
other cellular compartments are recognized by a subunit of COPII by their 
cytoplasmic tails and are thus sequestered together at the trans-ER face.  This was first 
described for the ER exit of the vesicular stomatitis virus G protein (VSVG) 
(Nishimura and Balch 1997).  Its cytoplasmic tail contains a di-acidic motif Asp-X-
Glu, which is recognized by the combination of activated Sar1p and Sec23p/24p, 
components of the COPII assembly.  The Sar1p/Sec23p/Sec24p complex at the ER 
exit site recruits two subunits each of Sec31p and Sec13p (Lederkremer et al. 2001; 
Sato and Nakano 2007).  The recruitment of multiple COPII complexes causes the 
curvature of the membrane and eventual budding and vesicle formation.  These 
vesicles are tagged by the small GTPase Ypt1 and travel to the cis-golgi, where the 
vesicles fuse and the contents are released into the golgi (Morsomme and Riezman 
2002).   
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How soluble cargo is selected is not quite as clear.  It is likely that there are 
transmembrane proteins that bind to ER cargo through non-specific means, possibly 
hydrophobic or ionic interactions.  In yeast, this has been shown that the soluble 
protein pro- -factor is recognized by the multispanning membrane protein Erv29p 
(Belden and Barlowe 2001).  This membrane protein binds a hydrophobic region in 
the pro region of the precursor molecule and sequesters it at the trans-ER face.  The 
cytosolic tail of Erv29p then interacts with COPII, leading to exit of the soluble 
proteins.  These signals that direct exit from the ER have been shown to be able to 
override ER retention signals and lead to the export of typically ER resident proteins 
(Otte and Barlowe 2004). 
 
Once within the golgi apparatus, proteins undergo final post translational 
modifications.  Misfolded molecules that manage to escape ER quality control are 
either transported back to the ER to undergo ER associated degradation, or are 
 
Figure 1-5-The mechanism for vesicle budding from the ER.  See text for details.  
Figure from Sato and Nakano 2007. 
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directed to the endosomal system for degradation (Arvan et al. 2002).  The details of 
how misfolded proteins are detected in the golgi are still being elucidated.  One 
protein involved in quality control in yeast is the golgi membrane protein Rer1p (Sato 
et al. 2001).  It has been shown to interact with other transmembrane domains and 
detect the presence of polar residues introduced by misfolding or mutation.  Rer1p 
then interacts with COPI, which is responsible for the retrograde transport of cargo 
from the golgi to the ER.  These misfolded proteins are then allowed to properly fold 
or are degraded.  
Trafficking and Docking With the Plasma Membrane 
From the golgi, cargo must be correctly targeted to a number of cellular locations, 
such as the vacuole, nucleus, and the cell exterior.  This requires the activation of a 
number of proteins at different steps, called a Rab cascade (Figure 1-6).  For secretion, 
newly formed vesicles are tagged with the small GTPase Ypt31/32, which travel along 
 
Figure 1-6-A Rab cascade is essential for secretory 
vesicle trafficking and tethering at the exocyst.  See 
text for details.  Image from Novick et. al 2006. 
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actin filaments towards the plasma membrane (Benli et al. 1996).  GTP bound 
Ypt31/32 recruits the protein Sec2, which activates the GTPase activity of Ypt31/32 
and its eventual release from the vesicle surface (Ortiz et al. 2002).  Sec2 then recruits 
another GTPase Sec4 in its GTP bound state and vesicle traffic proceeds towards the 
plasma membrane (Novick et al. 2006).  Sites of active secretion are differentiated by 
the presence of a large complex of proteins called the exocyst.  Sec4 binds to Sec15, 
an exocyst component, which displaces Sec2 and initiates the GTPase function of 
Sec4, leading to its release as well (Novick et al. 2006).  The Rab cascade serves to 
bring the secretory vesicle in close proximity to the plasma membrane and its tethering 
to the exocyst, a necessity for vesicle fusion and cargo release. 
 
The overexpression of molecules required for protein trafficking has been successful 
in enhancing protein secretion in both P. pastoris and S. cerevisae.  Sec4 
overexpression in P. pastoris led to the increased secretion of glucoamylase (Liu et al. 
2005) and in S. cerevisae to the increased secretion of -amylase (Toikkanen et al. 
2003).  As with chaperone overexpression, enhancement of the secretory pathway by 
elevating the levels of essential trafficking proteins is an important step to reducing 
and eliminating protein secretion bottlenecks. 
SNARES 
For vesicle fusion to occur, it is necessary that the vesicle and the target membrane are 
able to be brought together very tightly.  The class of proteins responsible for this 
critical step are called SNARE proteins (Soluble NSF Attachment protein REceptor).  
The discovery of SNARE proteins depended in large part on the study of the neuronal 
synaptic cleft, where vesicle fusion and release of neurotransmitters is critical for 
nervous system function.  In this system, the first proteins identified in vesicle fusion 
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were syntaxin (STX1), SNAP-25 (25 kDa synaptosome-associated protein), and 
VAMP (vesicle-associated membrane protein), also called syaptobrevin.  Initial 
classification systems divided SNARE proteins into v-SNAREs and t-SNAREs, 
depending on their location on the vesicle or target membrane (Chen and Scheller 
2001).  Refinements in understanding led to the renaming of the SNAREs as R-
SNAREs or Q-SNAREs, depending on the identity of a specific amino acid (arginine 
or glutamine) at a highly conserved region (Fasshauer et al. 1998).   
 
SNARE proteins are anchored to the membrane either as integral membrane proteins 
or are modified to contain lipid chains at their C-terminus (Burri L. and Lithgow T. 
2004).  Insertion of the integral membrane SNARE proteins proceeds through a 
pathway that has only recently begun to be defined in yeast.  SNARE proteins are 
recognized as they come off of the ribosome by the protein GET3, which scans all 
nascent polypeptide chains for the presence of C-terminal hydrophobic stretches.  
GET1 and GET2 recruit the GET3-SNARE protein complex which results in the 
insertion of the SNARE protein into the ER membrane (Schuldiner et al. 2008).  
Sorting of the SNARE proteins to the proper final destination takes place after this 
step, through currently unknown means.   
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Figure 1-7-Membrane fusion occurs when three SNARE molecules on the target 
membrane interact with one SNARE on the vesicle membrane.  A-The coiled coil 
structure that forms as the SNARE proteins assemble pulls the two membranes 
together to overcome repulsive ionic forces.  B-The fully formed SNAREpin and 
resultant fused membrane.  Image adapted from Südhof and Rothman 2009. 
Vesicle fusion requires the assembly of a four membered coiled coil, called a 
SNAREpin, containing 3 Q-SNAREs and 1 R-SNARE (Sutton et al. 1998).  After 
docking of the vesicle at the exocyst, SNAREs present on both the vesicle and the 
target begin to intertwine and “zip” together, pulling the vesicle and target membrane 
tightly together (Figure 1-7) (Südhof and Rothman 2009).  The energy generated by 
this zipping up process provides the energy necessary to overcome repulsive ionic 
forces between the membranes, and also to dissipate the hydration layer between the 
two membranes (Chen et al. 2001).  The amount of energy released by SNAREpin 
formation has been shown to be ~35 kbT, while the energy required to fuse the bilayers 
is 50-100 kbT, indicating that each vesicle fusion event will require the formation of 
three stable SNAREpin structures (Li et al. 2007). 
 
It is apparent that there are a number of steps where proteins can get retained on their 
path out of the cell, and consequently specific areas that can potentially be 
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manipulated to enhance the secretory capacity of the expression system.  Proper signal 
peptide selection is important to ensure a steady flow of protein into the ER.  If a 
protein quickly aggregates in the cytoplasm and obscures a post-translational signal 
peptide, no amount of downstream manipulation will lead to high secretion yields.   
 
Furthermore, if a protein is unable to fold in the unique environment of the ER, it will 
simply face retrograde transport out of the ER and be degraded.  Assuming 
translocation and folding are possible, then manipulation of the accessory proteins 
involved in the remainder of the secretory pathway is an attractive target for enhancing 
secreted protein yields.   
Unconventional Protein Secretion 
Because of the advantages to downstream purification offered by protein secretion, it 
is worth the time and energy required to generate strains that secrete protein with high 
yields.  Certain proteins, however, seem to be completely resistant to secretion by 
traditional methods.  Recent work has indicated that there are a number of proteins 
that are secreted by cells through routes that do not involve the traditional ER-golgi 
pathway.  Work is currently being done to elucidate the pathways involved, but it 
seems clear that the pathways are highly specific for a particular protein.  Multiple 
proposals have been put forward to explain how each of these molecules reaches the 
extracellular space, and can be seen in Figure 1-8.  These proposals fall into four 
primary categories: direct translocation of proteins across the membrane; lysosomal 
secretion; secretion by fusion of multivesicular bodies with the plasma membrane; and 
secretion by plasma membrane blebbing and vesicle shedding (Nickel and Rabouille 
2009).  At this early stage, however, it appears that there is not one conserved pathway 
involved, but that each protein that secretes by unconventional methods has evolved 
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its own unique secretion method.   
 
Of the proteins identified to undergo this process, the most well studied is fibroblast 
growth factor 2 (FGF-2).  The current model for secretion begins first with the finding 
that FGF-2 is capable of binding to the phosphoinositide phosphatidylinositol 4,5 
bisphosphate (PIP PI(4,5)P2).  This molecule is known to form islands in the plasma 
membrane, so it is currently thought that these islands recruit FGF-2 to the inner 
leaflet of the plasma membrane (Engling et al. 2002).  What happens after recruitment 
to result in extracellular FGF-2 is still under debate.  There are three proposed routes 
out of the cell (Nickel and Seedorf 2008).  The first requires a transport channel to 
allow the passive diffusion of FGF-2 across the membrane to the extracellular space.  
The second proposal requires a conformational change upon binding to PI(4,5)P2 to a 
conformation that would readily pass through the membrane.  This is unlikely, as 
fusion proteins between FGF-2 and GFP are also able to secrete with no apparent loss 
of efficiency (Engling et al. 2002; Florkiewicz et al. 1995), and it is difficult to 
rationalize how the GFP fusion protein would participate in this process.  The third 
possibility is that FGF-2 multimers are able to adopt a conformation that allows their 
passage through the membrane (Facchiano et al. 2003; Nickel et al. 2008).  Detailed 
secretion pathways for FGF-2 and other unconventionally secreted proteins are 
currently being elucidated.   
Enolase as an Unconventionally Secreted Protein 
There are multiple examples of other, well studied cytoplasmic proteins that are often 
found in the extracellular space, however at this point their classification as 
“unconventionally secreted” proteins is still up for debate.  Many of these proteins are 
highly expressed in the cytoplasm, and it is thought that their localization in the 
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extracellular space is simply due to small amounts of cell lysis (Klis et al. 2007).  One 
of these proteins is enolase, a highly expressed cytoplasmic protein that is involved in 
the conversion of 2-phosphoglycerate to phosphoenolpyruvate.  It has been found in 
the extracellular space in a number of organisms, including gram positive bacteria 
such as Lactobacillus crispatus (Antikainen et al. 2007) and Listeria monocytogenes 
(Schaumburg et al. 2004), the trematodes Schistosoma mansoni (Knudsen et al. 2005) 
and Echinostoma caproni (Marcilla et al. 2007), and in the yeast Candida albicans 
(Pitarch et al. 2004).  Many of these studies have attempted to control for cell lysis in a 
variety of ways and have concluded that the presence of enolase in the extracellular 
space is not simply an artifact.  Until the export mechanism is fully defined, its 
identity as an unconventionally secreted protein will be questioned. 
 
In C. albicans and other pathogenic organisms, enolase expression and display on the 
cell surface has a role in disease progression.  It has been shown that enolase is 
capable of binding to plasminogen, aiding in tissue invasion and increasing 
pathogenicity (Jong et al. 2003).  Furthermore, an immune response against C. 
albicans enolase is indicative of survival and recovery from systemic candidiasis 
(Pitarch et al. 2004).   
 
Enolase, along with a number of other proteins involved in glycolysis, has been shown 
to have a variety of different functions within the cell.  These proteins have been 
termed moonlighting proteins (Gancedo and Flores 2008).  Enolase has been ascribed 
a number of different activities in addition to its main role in the conversion of 2-
phosphoglycerate to phosphoenolpyruvate.  Eno2 has been shown to be required in the 
import of mitochondrial tRNA into the mitochondrion, while Eno1 was shown to 
perform this function as well, although with reduced efficiency (Entelis et al. 2006).  
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This function was shown to be independent of the enzymes function in glycolysis, as a 
mutant with 1% glycolytic activity was still able to direct tRNA import.   
 
A second activity that has been demonstrated for enolase is the homotypic fusion of 
vacuoles in S. cerevisae.  The addition of recombinant, purified Eno1 or Eno2 in an in 
vitro vacuole fusion assay showed that enolase was able to stimulate fusion in a dose 
dependent manner (Decker and Wickner 2006).  Enolase knockout strains also 
demonstrated a fragmented vacuole phenotype.  As with mitochondrial tRNA import, 
this function was demonstrated to be independent of enzyme function (Decker et al. 
2006).  Other studies have shown that enolase is capable of binding to phospholipids 
(Zhu et al. 2001), an ability which could be crucial in both its moonlighting functions 
 
Figure 1-8-Potential mechanisms of unconventional cytoplasmic 
protein export.  See text for details.  Image from Nickel and 
Rabouille 2009. 
 41 
and also for its ability to be secreted. 
 
Enolase has been used in S. cerevisae to direct the secretion of both invertase and GFP 
to the extracellular space (López-Villar et al. 2006).  In these experiments, invertase 
expressed intracellularly was unable to allow the growth of invertase deficient mutants 
on sucrose plates, while enolase fusions grew effectively, indicating that the fusion 
was being specifically released to the extracellular space and was not simply released 
by lysis.  Furthermore, the ability to direct the extracellular localization was 
determined to reside within the N-terminal 169 amino acids.  This data was confirmed 
with GFP fusions, which were shown to be localized to the plasma membrane through 
confocal microscopy.  Neither fusion protein showed evidence of glycosylation, 
further indicating that secretion did not rely on the ER-golgi pathway.  More research 
is needed into the unconventional secretion of enolase and other proteins to define 
their secretory pathway and to understand how and why this has evolved. 
Conclusion 
The impact of recombinant proteins in our everyday lives is only now starting to be 
realized.  Although industrial applications such as enzymatic cleaners have been 
around for many years, new markets such as biofuel production are quickly emerging 
that will benefit from the fast and efficient production of purified proteins.  The 
market for therapeutic proteins such as monoclonal antibodies is young and continues 
to grow at a fast pace.  Purified proteins are needed in many aspects of basic scientific 
research to advance our current knowledge and to develop new applications for 
biologically derived material.  All of these endeavors stand to benefit from increased 
research and understanding of the microbial factories central to protein production.  
Knowledge of the secretory pathway of P. pastoris will enable researchers to select 
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strains and growth conditions optimized to effectively secrete many difficult proteins.
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Chapter 2-The Expression of the Cancer Testis 
Antigen NY-ESO-1 in Pichia pastoris 
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Abstract 
NY-ESO-1 is currently one of the most attractive proteins for cancer immunotherapy.  
Expressed highly in a wide array of cancers, and limited to expression in testicular 
tissue in normal cells, it is an excellent marker for the immune system to use to 
differentiate between normal and cancerous cells.  The expression of NY-ESO-1 in 
Escherichia coli has led to the production of protein that is currently being used in 
clinical trials, but there is a need for a secondary source of NY-ESO-1 for use in skin 
testing of vaccine recipients.  The yeast Pichia pastoris was engineered to secrete NY-
ESO-1 to the culture supernatant, but during its passage through the cell, it gets 
retained and is only seen when the cells are disrupted and solubilized with detergents 
or urea.  Furthermore, the protein extracted from the cells in this fashion is not 
processed and is ~10 kDa larger than the wild type protein due to the retention of the 
-mating factor secretion signal.  This protein was prepared in a high cell density 
fermentation, and attempts to purify the protein by metal affinity chromatography 
were performed.  It was discovered that the C-terminal 6X his-tag included to aid in 
purification was being removed within the cell by unknown processes.  The C-
terminal arginine was removed by site directed mutagenesis to delete a putative Kex2 
protease site, and the new construct did indeed retain the his-tag.  These results 
suggest that NY-ESO-1 is inserted into the membrane upon translocation into the ER.  
The topology of the protein is such that the C-terminus is within the ER/golgi lumen, 
where the his-tag is cleaved by Kex2 protease. 
Introduction 
An important aspect of vaccination is determining that the immune response seen in 
the patient is indeed in response to the vaccine itself and not any contaminants present.  
When vaccinating with a recombinant protein, it is vital that the patient elicit a 
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response to the recombinant protein and not contaminating proteins from the 
expression host.  One way to measure the specificity of the response is by 
administering a delayed-type hypersensitivity (DTH) test (Davis et al. 2004).  In this 
test, a small amount of protein derived from a different source than the original 
vaccine is injected directly under the dermis.  A patient who has elicited a prior 
cellular immune response to the protein will demonstrate a response within 24-72 
hours.  Patients who have not been vaccinated will not respond.  This test is commonly 
used to test for prior exposure to tuberculosis (Vukmanovic-Stejic et al. 2006).   
 
Treatment of cancer using the patient’s own immune system is showing promise, with 
new vaccination strategies being developed to stimulate the immune system to 
recognize tumors as non-self.  To do this, it is necessary to identify markers that exist 
on the surface of tumors that are not present on normal tissue.  One such marker that 
has been identified in a number of different tumor types is the protein NY-ESO-1 
(Wang et al. 1998).  This protein was originally discovered in esophageal cancer, and 
has shown promise as a vaccine in a number of Phase I clinical trials at extending the 
survival of cancer patients (Jäger et al. 2000; Chen et al. 2004; Davis et al. 2004).  To 
date, NY-ESO-1 used in these trials has been derived from Escherichia coli expression 
systems, and it is important to verify that the immune response is to the NY-ESO-1 
protein and not residual E. coli host protein.  To achieve this, it is necessary that a 
source of NY-ESO-1 be developed that is produced in a different expression strain. 
 
The methylotrophic yeast Pichia pastoris is an attractive protein expression system as 
it is simple to transform with a gene of interest, grows to very high cell densities, and 
its ability to secrete many proteins facilitates downstream purification (Cereghino and 
Cregg 2000).  NY-ESO-1 derived from P. pastoris would make an ideal DTH reagent.  
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Responses to the P. pastoris DTH test would be a good indication that the immune 
response to NY-ESO-1 is real and not an artifact due to responses to E. coli derived 
contaminants.  To that end, P. pastoris was transformed with NY-ESO-1 containing a 
C-terminal his-tag, the protein produced in a high-cell-density fermentation, and the 
protein purified using methods developed for E. coli derived NY-ESO-1 purification. 
Materials and Methods 
Plasmid Construction 
The NY-ESO-1 gene was amplified by PCR from E. coli pET9a24a NY-ESO-1 
plasmid previously prepared in our lab for E. coli NY-ESO-1 production.  Primers 
were designed to add a 5' XhoI site and a 3' NotI site for cloning into pPICZ A 
(Invitrogen, Carlsbad, CA).  After PCR amplification, the product was cloned into 
pCR2.1 (Invitrogen, Carlsbad, CA) using the TOPO-TA cloning kit following 
manufacturer’s instructions.  Several successful transformants were selected and 
grown overnight in 2XYT medium and the plasmid DNA collected using the Qiaprep 
Spin Miniprep Kit (Qiagen, Valencia, CA).  Sequencing was performed using T7 High 
Temp and M13 Reverse universal primers at the Cornell University BioResource 
Center.  A plasmid with the proper sequence and the P. pastoris expression vector 
pPICZ A were digested with NotI and XhoI, run on a 1% (w/v) agarose gel, and the 
bands purified using the MinElute Gel Extraction Kit (Qiagen, Valencia, CA).  
Ligation was carried out using the Quick Ligation Kit (New England Biolabs, Ipswich, 
MA) following manufacturers instructions.  Ligation products were used to transform 
E. coli TOP10 and plated on LB supplemented with 25 µg/ml Zeocin (Invitrogen, 
Carlsbad, CA).  A resistant transformant was again grown overnight and the plasmid 
collected.   
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P. pastoris Transformation 
All P. pastoris transformations were carried out using the condensed transformation 
protocol described previously (Lin-Cereghino et al. 2005).  Briefly, a 5 ml YPD (1% 
yeast extract, 2% peptone, 2% dextrose) overnight culture was used to inoculate 50 ml 
YPD to an OD600 of 0.1-0.2.  After growth at 30°C to an OD600 of 0.8-1, the cells were 
harvested by centrifugation and resuspended in 9 ml BEDS buffer (10 mM bicine-
NaOH, pH 8.3, 3% (v/v) ethylene glycol, 5% (v/v) dimethyl sulfoxide, 1 M sorbitol) 
supplemented with 1 ml 1 M dithiothreitol (DTT).   After incubation for 5 min with 
gentle shaking at 30°C, the cells were again harvested by centrifugation and 
resuspended in 0.5 ml BEDS buffer.  40 µl aliquots of competent cells were mixed 
with 100 ng of plasmid that had been linearized with ClaI (New England Biolabs, 
Ipswich, MA) and purified with the MinElute Gel Extraction Kit (Qiagen, Valencia, 
CA).  Cells were electroporated using a GenePulser II (BioRad Laboratories, 
Hercules, CA) with settings of 1500 V, 200 Ω, and 25 µF in a 2 mm gap 
electroporation cuvette, and immediately resuspended in 1 ml YPD supplemented with 
1 M sorbitol.  After 1-2 hr at 30°C, cells were plated on YPDS with 100 µg/ml Zeocin.   
Fermentation 
Expression was carried out as described, with modifications (Damasceno et al. 2004).  
Briefly, a 50 ml YPD culture of each strain was grown to an OD600 of 8-10 and used to 
inoculate a 2.5 L working volume New Brunswick BioFlo 3000 fermentor (New 
Brunswick Scientific Company, Edison, NJ) containing 1 L of modified basal salts 
medium (0.23 g·L
-1
 CaSO4-2H2O, 4.55 g·L
-1
 K2SO4, 3.73 g·L
-1
 MgSO4-7H2O, 10.3 
g·L
-1
 KOH, 6.68 ml·L
-1
 H3PO4, 5% (v/v) glycerol) with 0.5 ml Antifoam 204.  15% 
(v/v) ammonium hydroxide was used to maintain the pH at 3.0 and also to serve as the 
nitrogen source.  Dissolved oxygen (DO) was controlled at 40% with a combination of 
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increasing agitation and pure oxygen supplementation.  After glycerol consumption 
during the batch phase, marked by a sharp increase in dissolved oxygen, a decreasing 
glycerol feed was initiated while the methanol probe was calibrated to transition the 
cells to methanol consumption.  Methanol feeding was controlled using a closed-loop 
PID scheme to maintain the methanol level at 1.0 g·L
-1 
(Damasceno et al. 2004) or a 
methanol limited fed batch using methanol feed to control DO (Jahic et al. 2003).  At 
this point, the temperature of the fermentation was also decreased to 15°C.  Samples 
were taken periodically to determine OD and wet cell weight, as well as protein 
concentration.  Clarified supernatant was prepared for SDS-PAGE by dilution with 4X 
LDS loading buffer (Invitrogen, Carlsbad, CA). 
Cell Lysis and Tangential Flow Filtration 
Fermentation broth was centrifuged at 4000 rpm in a swinging bucket centrifuge for 
30 minutes and the supernatant discarded.  The cell mass was resuspended in yeast 
breaking buffer (50 mM sodium phosphate pH 7.4, 1 mM EDTA, 5% (v/v) glycerol) 
in a Waring blender, and the cells lysed by five passes at 19000 psi in an Emulsiflex 
C3 microfluidizer (Avestin, Ottowa, ON).  The lysate was washed with five volumes 
of 100 mM sodium phosphate, pH 7.4, by tangential flow filtration using a 0.2 µM 
Centramate Cassette (Pall, East Hills, NY).   
Purification 
One volume of washed lysate was diluted into 3 volumes of 8.75 M urea, 100 mM 
phosphate pH 7.5 and allowed to mix at room temperature for four hr.  The solubilized 
material was then filtered through a 0.5 micron filter (Millipore, Billerica, MA) prior 
to chromatography.  Immobilized metal affinity chromatography (IMAC) was carried 
out using an AKTA Explorer FPLC equipped with a 5 ml HisTrap FF column (GE 
Healthcare, Waukesha, WI).  The column was equilibrated with IMAC Buffer A (4 M 
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urea, 100 mM phosphate pH 7.5).  A step gradient with IMAC Buffer B (4 M urea, 
100 mM phosphate pH 7.5, 0.5 M imidazole) was used for elution, with two steps at 
75 mM imidazole (low imidazole) and 500 mM imidazole (high imidazole).   
Analytical Methods 
Cell lysates were run on SDS-PAGE and stained with Simply Blue Safe Stain 
(Invitrogen, Carlsbad, CA).  Duplicate gels were blotted to nitrocellulose and probed 
with either monoclonal anti-NY-ESO-1 or anti-6X his-tag, alkaline phosphatase 
 
Figure 2-1-A fermentation profile for a methanol limited fed batch of P. pastoris.  
In this strategy, the methanol feed rate was adjusted to maintain dissolved oxygen 
concentration at 40%.  After the initial DO spike at 24 hours, the temperature of 
the culture was dropped to 15°C, a glycerol feed was begun, and the methanol 
probe calibrated once 15°C was reached.  After calibration, the glycerol feed was 
terminated and the methanol feed began.  The pH of the culture was maintained at 
3.0 by the addition of NH4OH.  The fermentation was terminated at 96 hours, at 
which point methanol consumption had slowed dramatically.
0
20
40
60
80
100
120
0
200
400
600
800
1000
1200
0:00:00 24:00:00 48:00:00 72:00:00 96:00:00
D
is
so
lv
ed
 O
x
y
g
en
 (
%
)
T
em
p
e
ra
tu
re
 (
C
)
A
g
it
a
ti
o
n
 (
rp
m
)
Agitation
Dissolved Oxygen
Temperature
 64 
tagged antibodies (Sigma, St. Louis, MO).  For LC-MS/MS, the band corresponding 
to NY-ESO-1 was visualized by coomassie staining of SDS-PAGE gels, excised and 
sent to the Cornell University BioResource Center for digestion with chymotrypsin 
and subsequent LC-MS/MS.   
Results 
NY-ESO-1 Fermentation 
In order to maximize NY-ESO-1 production in P. pastoris and minimize degradation, 
the fermentation process incorporates a limiting glycerol feed immediately after the 
 
Figure 2-2-A methanol limited fed batch and control 
process were run concurrently and the intracellular, 
insoluble protein fraction collected at different time points 
to look for NY-ESO-1 expression.  Protein fractions were 
run on SDS-PAGE and blotted to nitrocellulose 
membranes.  The membranes were probed with anti-NY-
ESO-1 monoclonal antibodies.  Wild type NY-ESO-1 from 
E. coli migrates at ~22 kDa, while the NY-ESO-1 from P. 
pastoris migrates at ~32 kDa, reflecting the lack of -
mating factor ( -MF) signal peptide cleavage.  L-Protein 
ladder.  +-NY-ESO-1 standard.  C-Control fermentation 
samples.  M-MLFB fermentation samples. 
-MF-NY-
ESO-1 
NY-ESO-1 
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initial batch phase to transition the cells to methanol consumption.  This is done in 
combination with a decrease in temperature from 25°C to 15°C.  These two changes 
minimize cell death upon methanol induction while enhancing the NY-ESO-1 content 
within the cells (data not shown).  A typical fermentation profile is shown in Figure 2-
1.   
 
Despite the presence of the -mating factor secretion signal on its N-terminus, NY-
ESO-1 fails to secrete from the cell.  Low levels of protein can be detected within the 
intracellular soluble fraction by western blotting, while the majority of the protein 
remains within the cell in an insoluble form.  Previous data has shown that NY-ESO-1 
 
Figure 2-3-Initial downstream processing of NY-ESO-1 from P. pastoris.  Cells 
from a high cell density fermentation were collected by centrifugation and 
resuspended in yeast breaking buffer.  Lysis was done by five passes through a 
microfluidizer at 19,000 PSI, and the insoluble aggregates washed with 100 mM 
phosphate buffer (pH 7.4) by tangential flow filtration with a 0.2 µm PES filter.  
The lysate was solubilized in three volumes of 8.75 M urea overnight before 
filtration through a 0.5 µM filter prior to chromatography.  Samples were run on 
SDS-PAGE, blotted to nitrocellulose, and probed with anti-NY-ESO-1 antibodies.  
L-Protein Marker.  +-NY-ESO-1 positive control.  1-Early TFF permeate.  2-Late 
TFF permeate.  3-Pre-solubilized lysate.  4-Urea-solubilized lysate.  5-SDS-
solubilized lysate.  6-Post-filtration. 
NY-ESO-1 
-MF-NY-ESO-1 
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colocalizes with the ER resident chaperone BiP, indicating that it enters the secretory 
pathway but is unable to be properly folded and secreted (data not shown).  Removing 
the signal peptide prevents NY-ESO-1 accumulation in all cellular compartments.  
This could indicate that the insertion of NY-ESO-1 into the secretory pathway 
sequesters and protects the protein from degradation by intracellular proteases.   
 
A time course study shows that NY-ESO-1 protein accumulates in the insoluble 
fraction over time, and the protein is larger than expected due to the lack of -mating 
factor cleavage (Figure 2-2).  Two different fermentation strategies were employed for 
the production of NY-ESO-1 in P. pastoris that differ in methanol feeding.  The 
control method, in which methanol concentration is maintained at 1 gL
-1
, has been 
very successful for the production of A33 scFv (Damasceno et al. 2004).  The NY-
ESO-1 yields from the intracellular insoluble fraction over time can be seen in Figure 
2-2, Lane C.  The second fermentation strategy uses the methanol feed to maintain the 
DO of the fermentation at 40%, and protein yields from this strategy can be seen in 
Figure 2-2, Lane M.  This feeding strategy limits the concentration of methanol in the 
culture, which has been demonstrated to result in less cell death (Jahic et al. 2003).  
Both fermentation strategies yielded similar levels of NY-ESO-1 in the intracellular 
insoluble fraction at 86 hours.  The MLFB strategy, however, had a more rapid 
accumulation of protein in the early stages of induction (Figure 2-2, 26 and 39 hours).  
Using the MLFB strategy, we were able to get sufficient quantities of protein for 
downstream purification studies. 
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Cell Lysis and Insoluble Fraction Washing 
The location of the bulk NY-ESO-1 in the insoluble phase led to using a purification 
method developed for E. coli derived inclusion bodies.  Cells were lysed with a 
microfluidizer, and the lysate was washed via tangential flow filtration using a 0.2 µM 
filter to remove soluble protein and other contaminants.  Analysis of the filter 
permeate by Western blotting shows that NY-ESO-1 does not pass through the 
membrane, as is seen with E. coli inclusion bodies (Figure 2-3, Lanes 1 and 2).  
Washing of the NY-ESO-1 aggregates by TFF removes many soluble contaminants 
(Figure 2-4, Lane 1), and also concentrates the protein to facilitate further downstream 
purification steps.   
 
Figure 2-4-NY-ESO-1 purification by metal affinity chromatography.  A 5 ml 
IMAC column was equilibrated with a 100 M phosphate, 4 M urea solution and 10 
ml solubilized lysate loaded onto the column.  The flow through, low imidazole, 
and high imidazole elutions were run on duplicate SDS-PAGE gels and stained 
with coomassie (left) or blotted to nitrocellulose and probed with anti-NY-ESO-1 
antibodies.  L-Protein Marker.  +-NY-ESO-1 standard.  1-TFF permeate.  2- Pre-
solubilized lysate.  3-Post-solubilized lysate.  4-Post-0.5 µM filtration/IMAC load.  
5-IMAC flow through.  6-Low imidazole elution.  7-High imidazole elution. 
 
 68 
Solubilization and Immobilized Metal Affinity Chromatography 
The washed lysate was mixed with three volumes of an 8.75 M urea, 100 mM 
phosphate buffer to solubilize NY-ESO-1 aggregates.  After mixing for at least 4 
hours, the solution was filtered through a 0.5 µM filter to remove any large particles.  
Filtration did result in a loss of NY-ESO-1 as shown by immunoblotting (Figure 2-3, 
lane 6), suggesting that lysis and solubilization methods are not sufficient to fully 
disrupt the cells and NY-ESO-1 aggregates.  The inclusion of SDS in the solubilization 
of a small aliquot of the washed lysate did seem to support this conclusion as it 
appears to have higher yields of NY-ESO-1 (Figure 2-3, lane 5), however this material 
was clarified by centrifugation and not filtration, making this comparison difficult.  
The filtered, solubilized lysate was loaded onto a 5 ml HisTrap FF column, and the 
flow through and elution fractions analyzed.  NY-ESO-1 was present in the flow 
through, as well as in the low imidazole fractions (Figure 2-4, Lanes 5 and 6).  Trace 
amounts of NY-ESO-1 were seen in the high imidazole fraction (Figure 2-4, Lane 7).  
Binding to the IMAC was poor, and its gradual elution from the column in all fractions 
suggests that any interaction was non-specific.   
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NY-ESO-1 Does Not Contain the Histidine Tag 
The NY-ESO-1 construct includes a C-terminal 6X his-tag to facilitate purification.  
IMAC chromatoagraphy shows that NY-ESO-1 binds to the column but simply 
washes out for the remainder of the run.  This suggests that the his-tag is either not 
present in the final protein product or is obscured by the folding of the protein, and the 
binding seen is nonspecific in nature (Figure 2-4).  Further evidence for this can be 
seen as NY-ESO-1 from P. pastoris not being detected by anti-6X his-tag antibodies 
(data not shown).  Detection of NY-ESO-1 could also not be seen even with a 4X his 
antibody, suggesting that folding and aggregation of the protein may not be simply 
obscuring the his-tag.  LC-MS/MS analysis of NY-ESO-1 detected no peptides 
containing the his-tag, but did detect a peptide that terminated directly upstream of the 
his-tag with the C-terminal –RR amino acids of the wild type NY-ESO-1 sequence 
(Figure 2-5).   
MRFPSIFTAVLFAASSALAAPVNTTTEDETAQIPAEAVIGYSDLEGDFDVA
VLPFSNSTNNGLLFINTTIASIAAKEEGVSLEKR EAEAMQAEGRGTGGS
TGDADGPGGPGIPDGPGGNAGGPGEAGATGGRGPRGAGAARASGPGG
GAPRGPHGGAASGLNGCCRCGARGPESRLLEFYLAMPFATPMEAELAR
RSLAQDAPPLPVPGVLLKEFTVSGNILTIRLTAADHRQLQLSISSCLQQLS
LLMWITQCFLPVFLAQPPSGQRRHHHHHH 
 
Figure 2-5-LC-MS/MS analysis of P. pastoris derived NY-ESO-1.  The NY-
ESO-1 sequence including the N-terminal secretion signal and the C-terminal 
6X histidine tag.  The Kex2 cleavage site is indicated by Peptides detected 
by LC-MS/MS are highlighted.  
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Kex2 Processes the His-tag in the Golgi 
LC-MS/MS results led to the hypothesis that the his-tag is getting cleaved at the –RR 
motif by the golgi resident Kex2 protease.  To test this, one arginine residue was 
removed from the NY-ESO-1 sequence by PCR to generate NY-ESO-1 R180, and the 
new construct was transformed into P. pastoris KM71H.  Five ml cultures were grown 
in BMM pH 6.0 for 48 hours at 15°C, the cells lysed with glass beads, and the 
intracellular, insoluble lysate dot-blotted onto nitrocellulose.  Duplicate membranes 
were screened with anti-NY-ESO-1 and anti-6X his-tag antibodies, and a clone was 
identified that was reactive to both (data not shown).  This clone was allowed to 
express for another 24 hours, and the intracellular insoluble extract analyzed by SDS-
PAGE and western blotting with anti-NY-ESO-1 and anti-6X his-tag antibodies 
(Figure 2-6).  Probing with anti-NY-ESO-1 antibodies detects protein from both 
cultures, while NY-ESO-1 R180 migrates slightly higher (Figure 2-6, B).  
Degradation of the NY-ESO-1 can be seen in both protein extracts, although the level 
of background staining is high due to overloading of the gel.  As has been 
demonstrated before, the control NY-ESO-1 protein is undetectable by anti-6X his-tag 
antibodies, however NY-ESO-1 R180 is effectively detected, clearly demonstrating 
the maintenance of the his-tag on the protein (Figure 2-6, C). 
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Discussion 
The cancer antigen NY-ESO-1 has the potential to be an effective weapon in the fight 
against cancer.  Its expression and purification from E. coli has been completed, and 
clinical trials are ongoing to determine the best vaccination strategy.  While the 
secretion of this protein in P. pastoris has been unsuccessful, there is still potential for 
this expression system to produce a version of NY-ESO-1 that will be used as a skin 
test antigen.  Skin testing will allow clinicians to quickly and easily identify responses 
to the E. coli derived vaccine.   
 
Despite the presence of the -mating factor secretion signal, NY-ESO-1 protein does 
not reach the extracellular space.  It is also not found in the cytoplasm, but instead is 
 
 
Figure 2-6-Five ml P. pastoris cultures of the (1) control NY-ESO-1 
and (2) NY-ESO-1 R180 were grown in BMM pH 6.0 at 15°C for 72 
hours.  The intracellular insoluble lysates were run on SDS-PAGE 
and blotted onto duplicate nitrocellulose membranes and probed with 
either anti-NY-ESO-1 or anti-6x his antibodies.  A-SDS-PAGE.  B-
Anti-NY-ESO-1 immunoblot.  C-Anti-6x his tag immunoblot. 
Anti-NY-
ESO-1 
Anti-6X His 
NY-ESO-1 
NY-ESO-1 
R180 
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only liberated from the cells when they are disrupted with detergents, indicating it is 
either embedded in the membrane, in the lumen of intracellular organelles, or found as 
large insoluble aggregates within the cell, similar to bacterial inclusion bodies.  
Furthermore, N-terminal sequencing showed that the signal sequence is not removed, 
resulting in the final protein being ~10 kDa larger than expected (data not shown).  
Confocal microscopy had previously shown that NY-ESO-1 and the ER resident 
chaperone BiP colocalize within the cell (unpublished results).  The resolution of this 
technique could not determine whether or not it was within the ER lumen or inserted 
within the membrane, however analysis of the amino acid sequence with the program 
SPLIT 4.0 predicts a strong transmembrane domain at the C-terminus of the protein 
(Juretić et al. 2002).  Regardless of its localization, the -mating factor is essential for 
the production of the protein, as its removal for intracellular expression prevented the 
accumulation of the protein (data not shown).  Secretion signal recognition leads to the 
full length protein being sequestered and protected from degradation within the cell. 
 
Previous work with NY-ESO-1 in P. pastoris showed that the culture must be 
maintained at 15°C for maximal protein production.  Temperatures higher than this 
lead to little NY-ESO-1 accumulation.  With intracellular expression, it is important to 
generate high levels of biomass, and at this temperature P. pastoris grows well, 
resulting in wet cell weights >250 gL
-1
.  Another factor shown to impact NY-ESO-1 
production in this system is the type of feeding strategy.  The typical fermentation 
strategy has the methanol concentration in the vessel controlled by an external 
methanol probe and pump to keep the concentration constant at 1 gL
-1
.  With NY-
ESO-1, another strategy was implemented to maintain the methanol at the lowest 
possible concentration and further slow production of NY-ESO-1.  A methanol limited 
fed batch (MLFB) was performed where methanol feeding was controlled by 
 73 
dissolved oxygen (DO) concentration (Jahic et al. 2003).  As methanol was consumed, 
dissolved oxygen would rise as the cells ran out of carbon.  This initiated the feed 
pump, and as DO dropped, the pump slowed and eventually stopped.  While this 
control was crude and resulted in noisy control of dissolved oxygen and agitation 
(Figure 2-1), NY-ESO-1 production was higher at 26 and 39 hours EFT (Figure 2-2).  
While the amount of NY-ESO-1 seen at the end of the fermentation was nearly the 
same in both the MLFB and control process, the use of the MLFB strategy would 
allow earlier termination of growth while maintaining high yield.   
 
The location of NY-ESO-1 in the insoluble intracellular fraction was not unexpected, 
as the C-terminal portion of the protein is highly enriched with hydrophobic residues.  
In E. coli expression, the protein is found exclusively within inclusion bodies, and the 
purification requires high concentrations of urea to keep the protein soluble.  As the 
final protein is used as a vaccine and does not require functional NY-ESO-1, the entire 
purification is carried out with 4 M urea.  We chose to explore the possibility of 
adapting this purification strategy for use with this system.  The first critical step is the 
washing of the insoluble fraction by tangential flow filtration.  Experience with E. coli 
shows that the NY-ESO-1 inclusion bodies are unable to pass through a 0.2 µM PES 
filter, allowing the wash of inclusion bodies with Tris and phosphate buffers.  This 
process removes many soluble proteins and concentrates the insoluble fraction.  This 
method was shown to be effective for P. pastoris lysate, and no NY-ESO-1 was found 
in the TFF permeate (Figure 2-3, lanes 1 and 2).   
 
Solubilization of the P. pastoris lysate was done as with E. coli, by diluting the washed 
lysate in 3 volumes of 8.75 M urea.  Any remaining large particles after this step are 
removed by filtration through a 0.5 µM filter.  Lysis and solubilization are two areas 
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where yields could be improved, as filtration did seem to remove NY-ESO-1 from the 
final preparation (Figure 2-3, Lane 6).  This suggests that lysis could be inefficient, 
and visualization of P. pastoris lysate after five passes through the microfluidizer 
showed that the cells were still largely intact but dead as shown by staining with 
propidium iodide.  The use of detergents in the lysis step could help to alleviate this 
problem, however this could lead to foaming during microfluidization. 
 
Metal affinity chromatography is the primary purification step with E. coli derived 
NY-ESO-1, but with P. pastoris NY-ESO-1, binding to the IMAC column was poor, 
with only non-specific interactions occurring and the protein bleeding out throughout 
the column wash and elution.  This observation prompted us to ensure the presence of 
the his-tag on the protein.  Detection of the protein by western blotting with anti-his 
antibodies is very effective in E. coli, but in this work no detection occurred, however 
the use of anti-NY-ESO-1 efficiently detected the protein.  An example in the literature 
with erythropoietin (EPO) suggested that the his-tag may be buried within the protein 
and undetectable with antibodies specific for a 6X his-tag (Debeljak et al. 2006).  The 
use of antibodies specific to only four histidines was shown to detect EPO, however 
with this antibody there was still no detection of NY-ESO-1.  Sequencing of the 
expression cassette from the P. pastoris genome confirmed that the his-tag was present 
in the coding sequence.  The protein was sent for LC-MS/MS, which showed that the 
his-tag was indeed not present in the final protein, however a fragment directly 
upstream of the his-tag was detected.   
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Figure 2-7-Membrane protein topology analysis of NY-ESO-1 from P. pastoris.  
The full length NY-ESO-1 sequence containing the -mating factor signal peptide 
was analyzed by CONPRED II to determine membrane topology.  The 
cytoplasmic side of the membrane is designated by “in.”  The location of the –RR-
6XHis motif is predicted to be on the “out” side of the membrane, or within the 
ER/golgi lumen, where it would be susceptible to processing by Kex2 protease.  
The black arrow designates the predicted cleavage site for signal peptidase.  N 
terminal sequencing of the wild type NY-ESO-1 indicates that signal peptidase is 
unable to recognize and remove the pre region of the -mating factor.  
http://bioinfo.si.hirosaki-u.ac.jp/~ConPred2/ 
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The final two amino acids of the wild type NY-ESO-1 protein are both arginine.  We 
speculated that the his-tag is being cleaved after these residues by the golgi resident 
protease Kex2, which will recognize dibasic sequences such as –RR, albeit with 2-fold 
lower efficiency than with the consensus –KR sequence (Bevan et al. 1998).  It is 
possible that the protein is being inserted into the membrane in such a way that the C-
terminal his-tag is exposed to Kex2 within the golgi, but the N-terminal -mating 
factor is not.  The full length NY-ESO-1 sequence, with the attached -mating factor, 
was analyzed by the web based topology prediction program CONPRED II (Figure 2-
7) (Arai et al. 2004).  The output from this program shows that NY-ESO-1 has two 
transmembrane spanning domains, one within the signal peptide and the other at the 
C-terminal end.  The predicted orientation for this protein has the C-terminal end 
within the ER/golgi lumen, and thus susceptible to Kex2 degradation.  The Kex2 
sequence located within the signal peptide in this program is shown to be located 
within the cytoplasm, possibly explaining the lack of signal peptide cleavage.  To test 
this, one arginine was removed by site directed mutagenesis and the new construct 
transformed into P. pastoris KM71H.  A clone expressing NY-ESO-1, again in the 
intracellular insoluble fraction, was isolated and expressed in shake flask cultures.  As 
with the previous strains, there was no processing of the signal peptide, however the 
protein lacking the C-terminal arginine residue did indeed contain the 6X his-tag as 
determined by immunoblotting, supporting the hypothesis that Kex2 protease is 
removing the his-tag.  This strongly suggests that instead of forming insoluble 
aggregates, NY-ESO-1 is inserted into the ER membrane.  It is interesting to note that 
in humans, NY-ESO-1 localizatoin has been shown to be cytoplasmic in both tumor 
and testis tissue (Gnjatic et al. 2006).  Lacking any retention sequence, it likely traffics 
throughout the cell, coming in contact with Kex2 within the golgi.  Further 
experiments with confocal and electron microscopy to better characterize the 
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localization of this protein within the cell are warranted.  Future work to scale up the 
expression of this molecule and to adapt the E. coli based NY-ESO-1 purification 
scheme to this molecule is necessary to produce a viable reagent for skin testing. 
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Chapter 3-The Cooverexpression of A33 scFv 
and the S. cerevisae SNARE proteins Sso1 and 
Snc2 in Pichia pastoris 
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Abstract 
The secretion of A33 scFv by Pichia pastoris was shown to be enhanced by the 
cooverexpression of the Saccharomyces cerevisae SNARE protein Sso1.  P. pastoris 
has proven to be capable of secreting large quantities of heterologous proteins to the 
culture medium in its active state.  The simple medium and low levels of host proteins 
that are secreted into the supernatant facilitate downstream purification.  Efforts to 
improve secretory yields have mainly focused on optimizing culture conditions, but 
more recent work has focused on modulating the levels of proteins involved in the 
secretory pathway.  The S. cerevisae SNARE proteins Snc2 and Sso1 were cloned and 
expressed in P. pastoris GS115 that is also expressing the single chain antibody 
fragment targeting the colonic epithelium surface protein A33.  Neither Snc1 or Sso1 
impaired growth, however Snc2 overexpression was shown to inhibit A33 scFv 
secretion in 25 ml shake flask cultures.  In a high cell density fermentation, Snc2 
expression did not have any effect on A33 scFv yields.  Sso1 overexpression improved 
the secretion of A33 scFv by 31% in shake flask cultures, while in a high cell density 
fermentation, Sso1 enhanced secretion by 80% after 36 hours of fermentation.  These 
two SNARE proteins were then expressed in a P. pastoris strain which expresses both 
the A33 scFv and also the ER resident chaperone BiP.  The growth of triple 
transformants with A33 scFv, BiP and either Snc2 or Sso1 was impaired, and they 
secreted 43% and 34% less A33 scFv on a per cell basis, respectively. 
Introduction 
The expression of heterologous proteins in the methylotrophic yeast Pichia pastoris 
continues to gain in popularity due to its ease of use and high protein yields.  One of 
the more attractive aspects of the system is the ability to secrete large quantities of 
active protein, which becomes even more desirable when one considers the low 
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secretion levels of host proteins.  Once the cells are removed, the product is highly 
enriched, facilitating further downstream purification.  Success in terms of a viable 
method for producing a heterologous protein highlights the importance of studying 
and improving the secretion of heterologous proteins in this expression platform. 
 
There have been a number of strategies implemented to enhance protein production in 
a variety of microbial hosts.  In yeast, there has been a focus on the overexpression of 
chaperones in addition to the recombinant protein (Damasceno et al. 2007; Shusta et 
al. 1998; Inan et al. 2006).  This strategy is based on the assumption that the basal 
level of chaperones normally present in the cell is insufficient to properly fold the high 
levels of protein present when overexpressing a heterologous molecule.  This can 
especially be true in P. pastoris, where the most common promoter used to drive 
expression, AOX1, is highly induced when exposed to methanol (Tschopp et al. 1987; 
Ellis et al. 1985).  The overexpression of the chaperone Immunoglobulin Binding 
Protein (BiP) has successfully enhanced the secretion yield of A33 scFv from P. 
pastoris (Damasceno et al. 2007), and has also been helpful in the expression of 
hirudin in S. cerevisae (Kim et al. 2003).  Other strategies to improve secreted protein 
yield have focused on the overexpression of proteins involved at critical bottlenecks in 
the protein trafficking pathway.  In P. pastoris, the overexpression of the Rab GTPase 
Sec4, involved in secretory vesicle docking at the plasma membrane, has been shown 
to enhance the secretion of glucoamylase (Liu et al. 2005).  Other proteins acting 
throughout the secretory pathway could also have a role in enhancement of the 
secretory capacity, and we chose to test two SNARE proteins critical for membrane 
fusion with the plasma membrane, Snc2 and Sso1. 
 
SNARE proteins form a complex called a SNAREpin, with four individual SNARE 
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proteins involved in the generation of a coiled coil structure.  SNAREpin formation is 
thought to provide the energy required to overcome the repulsive forces generated 
when the membranes fuse (Chen and Scheller 2001).  In S. cerevisae, the SNAREpin 
at the plasma membrane is composed of one molecule each of Snc2 and Sso1, and two 
copies of Sec9 (Burri L. and Lithgow T. 2004).  Overexpression of the Kluyveromyces 
lactis SNARE protein Sso1 in S. cerevisae has been shown to enhance the secretion of 
-amylase more than two fold (Toikkanen et al. 2004).  For this work, the S. cerevisae 
Snc2 and Sso1 genes were cloned and placed under the control of the Pex8 methanol 
inducible promoter and transformed into P. pastoris secreting A33 scFv, an antibody 
fragment useful for targeting colon cancer cells, to examine their ability to enhance 
secretion of this clinically useful molecule.  Sso1 cooverexpression was shown to 
enhance A33 scFv yields in both shake flask cultures and high cell density 
fermentation, while Snc2 impaired protein secretion yields in shake flask cultures.  
The cooverexpression of both of these proteins concurrently with the ER resident 
chaperone BiP and the A33 scFv led to a decrease in growth rates, and a decrease in 
A33 scFv yield on a per cell basis. 
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Table 3-1-Primers used in vector construction.  EcoRI and NotI restriction sites are 
underlined. 
Primer Sequence 
Sso1 Forward 5'-GAATTCACGATGAGTTATAATAATCCGTAC-3' 
Sso1 Reverse 5'-GCGGCCGCTTAACGCGTTTTGACAACGGCTGGGACAA-3' 
Snc2 Forward 5'-GAATTCACGATGTCGTCATCAGTGCCATAC-3' 
Snc2 Reverse 5'-GCGGCCGCTTAGCTGAAATGGACGACGATAGGAACGAT-3' 
 
Materials and Methods 
Strains and growth conditions 
All cloning was carried out using Escherichia coli TOP10 (Invitrogen, Carlsbad, CA) 
according to manufacturers specifications.  The Snc2 and Sso1 genes were amplified 
by PCR from S. cerevisae genomic DNA.  P. pastoris GS115 carrying the A33 scFv 
gene in a Mut+ background were prepared as described (Pla et al. 2006).  GS200 cells 
harboring the chaperone BiP under the control of the AOX1 promoter were prepared 
as described (Damasceno et al. 2007).   
Plasmid Construction 
The Snc2 and Sso1 genes (GenBank accession numbers L16243.1 and X67729.1, 
respectively) were amplified by PCR from S. cerevisae genomic DNA.  Primers were 
designed to add a 5' EcoRI site and a 3' NotI site for cloning into pJS1 (Johnson et al. 
2001).  Primers used are indicated in Table 3-1.  After PCR amplification, the product 
was cloned into pCR2.1 (Invitrogen) using the TOPO-TA cloning kit following 
manufacturers instructions.  Several successful transformants were selected and grown 
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overnight in 2XYT medium and the plasmid DNA collected using the Qiaprep Spin 
Miniprep Kit (Qiagen, Valencia, CA).  Sequencing was performed using T7 High 
Temp and M13 Reverse universal primers at the Cornell University BioResource 
Center.  A plasmid with the proper sequence and the P. pastoris expression vector pJS1 
were digested with EcoRI and NotI, run on a 1% (w/v) agarose gel, and the bands 
purified using the MinElute Gel Extraction Kit (Qiagen, Valencia, CA).  Ligation was 
carried out using the Quick Ligation Kit (New England Biolabs, Ipswich, MA) 
following manufacturers instructions.  Ligation products were used to transform E. 
coli TOP10 and plated on Luria broth supplemented with 25 µg/ml Zeocin (Invitrogen, 
Carlsbad, CA).  A Zeocin resistant transformant was again grown overnight and the 
plasmid DNA collected.   
P. pastoris Transformation 
All P. pastoris transformations were carried out using the condensed transformation 
protocol described previously (Lin-Cereghino et al. 2005).  Briefly, a 5 ml YPD (1% 
yeast extract, 2% peptone, 2% dextrose) overnight culture was used to inoculate 50 ml 
 
Figure 3-1-Plasmids used in this study. 
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YPD to an OD600 of 0.1-0.2.  After growth at 30°C to an OD600 of 0.8-1, the cells were 
harvested by centrifugation and resuspended in 9 ml BEDS buffer (10 mM bicine-
NaOH, pH 8.3, 3% (v/v) ethylene glycol, 5% (v/v) dimethyl sulfoxide, 1 M sorbitol) 
supplemented with 1 ml 1 M dithiothrietol (DTT).   After incubation for 5 min with 
gentle shaking at 30°C, the cells were again harvested by centrifugation and 
resuspended in 0.5 ml BEDS buffer.  40 µl aliquots of competent cells were mixed 
with 100 ng of the appropriate plasmid that had been linearized with Cla1 (New 
England Biolabs, Ipswich, MA) and purified with the MinElute Gel Extraction Kit 
(Qiagen, Valencia, CA).  Cells were electroporated using a GenePulser II (BioRad 
Laboratories, Hercules, CA) with settings of 1500 V, 200 Ω, and 25 µF in a 2 mm gap 
electroporation cuvette, and immediumtely resuspended in 1 ml YPD supplemented 
with 1 M sorbitol.  After 1-2 hr at 30°C, cells were plated on YPDS with 100 µg/ml 
Zeocin.   
Small Scale Expression 
After 2-3 days, several transformants were picked and analyzed for A33 scFv 
secretion.  For small scale expression, 5 ml YPD cultures were grown overnight in 
YPD at 25°C and diluted the next day in 25 ml MD medium  (1.34% yeast nitrogen 
base, 4x10
-5
% biotin, 2% dextrose) to an OD600 of 0.1-0.5.  Growth was allowed to 
proceed to an OD600 of 1-5, the cells harvested by centrifugation, and resuspended in 
the same volume of MM medium (1.34% yeast nitrogen base, 4x10
-5
% biotin, 0.5% 
methanol) and transferred to 250 ml baffled Erlenmeyer flasks.  Cultures were 
supplemented with 100% methanol to 0.5% (v/v) every 12 hr.  Samples were 
centrifuged at 13000 rpm and the supernatants and cell pellets frozen at -20°C for 
further analysis. 
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Fermentation 
High cell density fermentation was carried out as described, with minor modifications 
(Damasceno et al. 2004).  Briefly, a 50 ml YPD culture of each strain was grown to an 
OD600 of 8-10 and used to inoculate a 2.5 L working volume New Brunswick BioFlo 
3000 fermentor (New Brunswick Scientific Company, Edison, NJ) containing 1 L of 
modified basal salts medium (0.23 g·L
-1
 CaSO4-2H2O, 4.55 g·L
-1
 K2SO4, 3.73 g·L
-1
 
MgSO4-7H2O, 10.3 g·L
-1
 KOH, 6.68 ml·L
-1
 H3PO4, 5% (v/v) glycerol) with 0.5 ml 
Antifoam 204.  15% (v/v) ammonium hydroxide was used to maintain the pH at 3.0 
and also to serve as the nitrogen source.  Dissolved oxygen (DO) was controlled at 
40% with a combination of regulating impeller speed and pure oxygen 
supplementation.  After glycerol consumption during the batch phase, which was 
marked by a sharp increase in dissolved oxygen, methanol feeding was initiated using 
a closed-loop PID control scheme to maintain the methanol level at 1.0 g·L
-1 
(Damasceno et al. 2004).  Samples were taken periodically to determine OD600 and 
wet cell weight, as well as protein concentration.   
Protein Methods 
Clarified supernatant was prepared for SDS-PAGE by dilution with 4X LDS loading 
buffer (Invitrogen, Carlsbad, CA).  Ten µl samples were loaded on 12% bis-tris gels 
and run at 100 V in MES buffer for 90 minutes.  Gels were stained either using 
coomassie (SimplyBlue Safe Stain, Invitrogen, Carlsbad, CA) or by silver staining 
(SilverQuest Staining Kit, Invitrogen, Carlsbad, CA) following manufacturers 
instructions.  Gels were dried using a DryEase gel drying kit (Invitrogen, Carlsbad, 
CA).  Gels were scanned, and the images were analyzed for image densitometry 
analysis using ImageJ (NIH, Bethesda, MD). 
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Real Time RT-PCR 
An aliquot of cells corresponding to an OD600 of 1.0 was centrifuged and the mRNA 
was harvested using the RNeasy Mini Kit (Qiagen, Valencia, CA) following 
manufacturer’s instructions.  Cells were lysed through mechanical disruption using 
acid washed glass beads.  RNA was quantified using a NanoDrop ND-1000 
Spectrophotometer (Thermo Scientific, Waltham, MA).  A total of approximately100 
ng of RNA was applied to each well of a 96 well rtPCR plate and a 2X stock of SYBR 
Green Master Mix (Sigma, St. Louis, MO) and the appropriate primers was added to 
each well.  Primer sequences are listed in Table 3-2.  Amplification was carried out 
using an ABI Prism 7000 Real Time Thermocycler (Life Technologies, Carlsbad, CA).  
Data analysis was performed using ABI Prism 7000 SDS Software. 
Results 
Overexpression of Snc2 in a Mut+ scFv Strain 
A Mut+ strain of P. pastoris expressing A33 scFv was transformed with the S. 
cerevisae gene encoding the V-SNARE Snc2 under the control of the methanol 
Table 3-2-Primers used for rtPCR. 
Primer Sequence 
AOX1 Reverse 5'-AAGTCCTTGGTTTTCCAGCCCTCGGC-3' 
AOX1 Forward 5'-GAGCCATTGTTCCATGTGCTAACGTCTTGG-3' 
Act1 Forward 5'-CCCACACACAGTGTTCCCATCGGTCGT-3' 
Act1 Reverse 5'-GGTGCCAGATCTTTTCCATATCGTCCCAGT-3' 
Snc2 Forward 5'-TATGTGCCTCCAGAGGAGAGTAA-3' 
Snc2 Reverse 5'-CTCAATGGATGTTAGCCTTTCAC-3' 
scFv Forward 5'-TGGAGATCAAAGGTGGTTCC -3' 
scFv Reverse 5'-GACTGAAGCCGATTCCAGAG-3' 
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inducible promoter Pex8.  This promoter allows induction on methanol, but at levels 
far less than the AOX1 promoter that was used to drive the A33 scFv expression.  
Image densitometry analysis of silver stained SDS-PAGE gels demonstrated that 
overexpression of Snc2 led to a decrease over time in A33 scFv yield in the 
supernatant (Figure 3-2).  After only 24 hours of induction, there was a 23% decrease 
in A33 scFv yield in the culture supernatant.  This value decreased further over time, 
with the 72 hour sample showing a 49% loss of A33 scFv compared to the control.  
Growth curves of all cultures showed that the decrease was not due to difference in 
cell growth.   
High Cell Density Fermentation 
An Snc2 overexpressing strain was chosen for high cell density fermentation.  
Previous work with the A33 scFv demonstrated that the protein is highly susceptible to 
degradation at pH 6, so all fermentations were done at pH 3.0 and 25°C (Damasceno 
 
Figure 3-2-The effect of Snc2 cooverexpression on A33 
scFv yields.  Mut+ strains of P. pastoris harboring the 
A33 scFv gene with and without the S. cerevisae Snc2 
gene were grown in 25 ml MM medium for 72 hours.  
Supernatants were collected, run on SDS-PAGE, and 
silver stained.  Gels were analyzed for scFv yield using 
image densitometry and the band intensities compared to 
the control to determine fold improvement. 
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et al. 2004).  When analyzed by SDS-PAGE, both the Snc2 overexpressing strain and 
the control strain had nearly identical A33 scFv yields after 36 hours of induction.  As 
was seen in the shake flask experiments, the growth of the Snc2 overexpressing strain 
was not impaired by the presence of the additional S. cerevisae gene.  OD600 values for 
both the Snc2 and control strain peaked at ~400, and the wet cell weight for both 
cultures reached ~450 gL
-1
.   
Real time RT-PCR 
As the inhibition seen in the shake flask cultures was not seen during fermentation, 
real time RT-PCR was performed to determine Snc2 expression levels in the 
fermentation.  Amplification was carried out using primers specific to Snc2 and A33 
scFv, with control primers for Aox1 and Act1.  Expression levels for scFv, Act1, and 
 
Figure 3-3-The expression of Snc2, A33 scFv, and 
AOX1 in strains of P. pastoris.  RNA samples from 
various time points during the fermentation of P. 
pastoris GS115 expressing A33 scFv with and 
without cooverexpression of Snc2 were analyzed by 
SYBR Green real-time rtPCR.  Primers against 
Snc2, A33 scFv, Aox1, and Act1 were designed, and 
Ct values were standardized against Act1. 
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Aox1 were similar in both cultures, and only the Snc2 culture had expression of the 
Snc2 gene, as expected (Figure 3-3).  Despite the efficient use of methanol for the 
duration of the fermentation, however, expression yields of A33 scFv and alcohol 
oxidase decreased over time.  Actin expression also decreased.  Snc2 expression levels 
in the Snc2 culture remained high throughout.  When normalized for Actin Ct, 
however, the expression levels of A33 scFv and Aox1 appear to be constant. 
Sso1 Overexpression 
Sso1 overexpression in shake flasks was performed to ascertain its effect on A33 scFv 
secretory yields.  25 ml shake flask cultures of several transformants showed that A33 
scFv yields were improved by the cooverexpression of Sso1 (data not shown).  One 
representative clone was selected for analysis in small scale fermentation.  In contrast 
with Snc2, overexpression of Sso1 in a high cell density fermentation resulted in 
enhancement of A33 scFv yield by 81% at 36 hours elapsed fermentation time as 
 
Figure 3-4-The effect of Sso1 on A33 scFv yield.  P. 
pastoris GS115 cooverexpressing A33 scFv with Sso1 
was grown in high cell density fermentation.  Aliquots of 
culture supernatant were adjusted for culture OD600 and 
prepared for SDS-PAGE.  Coomassie stained gels were 
scanned and analyzed using image densitometry. 
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determined by comparison of coomassie stained gels by image densitometry(Figure 3-
4).  The enhancement remained throughout the course of the fermentation, dropping to 
10% at the end of the fermentation at 71 hours.   
Sso1 or Snc2 Cooverexpression with BiP 
As Sso1 and Snc2 operate at the terminal end of the secretory pathway, it was 
hypothesized that any enhancements in secretory vesicle trafficking would not be 
apparent if there was a bottleneck earlier in the pathway.  To test this, Sso1 or Snc2 
were used to transform a strain of P. pastoris GS200 harboring the ER resident 
chaperone BiP under the control of the AOX1 promoter.  Earlier work demonstrated 
that this strain had an approximately three fold increase in secreted A33 scFv levels 
compared to controls (Damasceno et al. 2007).   
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Figure 3-5-Growth curves of SNARE and chaperone overexpressing 
strains of P. pastoris.  P. pastoris GS200 strains harboring A33 scFv were 
transformed with BiP and Snc2 or Sso1 (A33 scFv/BiP/Snc2 and A33 
scFv/BiP/Sso1, respectively), Snc2 alone (A33 scFv/Snc2), or empty 
vector controls (A33 scFv Control) and were grown in 25 ml MM cultures 
at 25°C for 84 hours.  OD600 values were taken every 12 hours starting at 
24 hours. 
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Strains expressing both BiP and either of the SNARE proteins exhibited slower growth 
than a control with neither BiP or SNARE proteins (Figure 3-5).  A GS200 strain 
without BiP but with Snc2 did not show this same defect in growth, indicating that the 
growth defect was due to the overexpression of all three proteins (A33 scFv, BiP, and 
either Snc2 or Sso1).  Despite the fact that the SDS-PAGE samples were adjusted for 
this difference in culture OD600, image densitometry analysis showed that the triple 
transformants still showed a marked decrease in scFv yields of 45% for A33 
scFv/BiP/Snc2 and 55% for A33 scFv/BiP/Sso1 (Figure 3-6).  As with the previous 
small scale expressions without BiP (Figure 3-2), Snc2 overexpression in P. pastoris 
GS200 led to a decrease in A33 scFv yield when compared with the control of 27% 
(Figure 3-6, A33 scFv/Snc2). 
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Discussion 
Many strategies are available to increase the yield of secreted recombinant proteins.  
The overexpression of ER resident chaperones in both S. cerevisae and in P. pastoris 
has been shown to improve the secretory yield of numerous scFv molecules 
(Damasceno et al. 2007; Shusta et al. 1998).  Overexpression of the Rab GTPase Sec4 
has led to the improvement of glucoamylase secretion in P. pastoris (Liu et al. 2005).  
This work focused on enhancing the capacity of the terminal end of the secretory 
pathway by the overexpression of SNARE proteins involved in the fusion of secretory 
vesicles with the plasma membrane. 
 
Overexpression of the K. lactis SNARE Sso1 in S. cerevisae has previously been 
shown to increase the yields of -amylase 2.2 fold (Toikkanen et al. 2004).  Using this 
work as a guide, we isolated the S. cerevisae genes for Sso1 and one of its partner, 
vesicle bound SNARE proteins Snc2.  Together with Sec9, the assembly of a 
SNAREpin complex at the vesicle-plasma membrane interface drives fusion of the 
membranes and the release of their contents into the extracellular space.  We 
hypothesized that increasing the available numbers of SNARE proteins would 
improve secretory yields in P. pastoris.   
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Sso1 overexpression in P. pastoris was not detrimental to cell growth.  Sso1 
overexpression had a positive effect on A33 scFv secretion, increasing yields by 31% 
in shake flask cultures.  In high cell density fermentations, scFv yields were increased 
by 81% after 8 hours of induction and 10% after 43 hours.  Snc2 overexpression in P. 
pastoris was shown to not impact the growth of the organism.  At the small scale, 
however, the cooverexpression of Snc2 and A33 scFv was shown to result in lower 
yields of scFv when compared with the control.  High cell density fermentations of the 
 
Figure 3-6-The effect of SNARE and BiP cooverexpression on 
A33 scFv yield.  P. pastoris GS200 cultures expressing A33 
scFv with different combinations of the chaperone BiP and the 
SNARE proteins Snc2 and Sso1 were grown in 25 ml MM at 
25°C for 24 hr.  Gel samples were prepared from culture 
supernatant at 60 hours and adjusted for culture OD600.  Ten µl 
samples were run in duplicate on SDS-PAGE gels, the gels 
dried, and analyzed by image densitometry.   
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same strains showed no appreciable defect in scFv yields, however there was no 
evidence of enhancement.  RT-PCR confirmed that transcription of the Snc2 gene was 
indeed occurring, suggesting that the protein product itself is inhibiting secretion of 
A33 scFv.   
 
It is interesting that Sso1 but not Snc2 enhanced secretory capacity.  Despite there 
being no defect in cell growth in these strains, the decreased secretory yields could be 
due to a slight metabolic burden on the organism deriving from the need to 
overexpress the SNARE protein in addition to the A33 scFv.  This is not likely, as the 
overexpression of chaperone molecules using the same promoter in P. pastoris has 
shown a marked increase in A33 scFv yields (Damasceno et al. 2007).  It is likely that 
the Snc2 sequence isolated from S.cerevisae is too divergent from the P. pastoris 
homolog to participate in the generation of a stable SNAREpin.  The genome 
sequence of P. pastoris GS115 was recently published and the P. pastoris Snc2 and 
Sso1 homologs were identified by searching with the S. cerevisae protein sequences 
used in this study.  An alignment of the Snc2 protein sequences shows that the S. 
cerevisae Snc2 sequence contains a five residue insertion directly upstream of the 
SNARE domain that begins at residue 28 (Figure 3-7).  The residues that are buried 
within the hydrophobic core of the SNAREpin are well conserved, but it is possible 
that this insertion and other differences at the N terminal end (residues 20-40) of the 
SNAREpin may be preventing initiation of the coiled coil domain formation.  The 
Sso1 homologs show no such insertions within or around the SNARE domain (Figure 
3-8).  While there are amino acid differences within the SNARE domain, the 
hydrophobic core residues are well conserved, providing further evidence that the S. 
cerevisae Sso1 homolog is functional in P. pastoris.   
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There has been a great deal of research looking at the specificity of SNARE 
interactions and the role they play in determining protein flow in the cell.  Out of 275 
possible SNARE combinations in S. cerevisae, only nine of them result in successful 
membrane fusion, and eight of those correspond to known pathways (Varlamov et al. 
2004).  This suggests that differences between S. cerevisae Snc2 and its P. pastoris V-
SNARE homolog would prevent the successful fusion of vesicles in P. pastoris that 
harbor the S. cerevisae Snc2 SNARE protein.  This would function as an inhibitory 
SNARE, lowering overall secretion efficiency by preventing the formation of 
successful SNAREpins.   
 
Figure 3-7-An alignment of the P. pastoris and S. cerevisae Snc2 protein 
sequences.  The protein sequences for the S. cerevisae Snc2 (GenPept Accession 
#CAA89974) was used to BLAST for the P. pastoris GS115 homolog (GenPept 
Accession #XP_002490822).  The sequences were aligned using DNAStar 
Lasergene 8.0 with the ClustalW method.  The residues predicted to reside in the 
hydrophobic core of the SNAREpin domain are highlighted in red. 
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The cooverexpression of BiP by our group in P. pastoris clearly showed that higher 
amounts of secretion are possible without the overexpression of machinery involved in 
the movement of secretory vesicles throughout the cell (Damasceno et al. 2007).  We 
hypothesized that these strains would derive greater benefit from SNARE 
overexpression, as these strains would be moving more protein through the secretory 
pathway.  The strains cooverexpressing A33 scFv, BiP, and either Sso1 or Snc2 
displayed a defect in growth that led to a corresponding decrease in scFv yield.  It is 
likely that the metabolic burden associated with the overexpression of three proteins, 
two of which are under the control of the strong, methanol inducible AOX1 promoter 
impairs cell growth.  Future work coupling the overexpression of chaperones and 
 
Figure 3-8- An alignment of the P. pastoris and S. cerevisae Sso1 SNARE domain 
protein sequences.  The protein sequences for the S. cerevisae Sso1 (GenPept 
Accession #CAA97949) was used to BLAST for the P. pastoris GS115 homolog 
(GenPept Accession #XP_002490413).  The sequences were aligned using 
DNAStar Lasergene 8.0 with the ClustalW method.  The residues predicted to 
reside in the hydrophobic core of the SNAREpin domain are highlighted in red. 
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SNARE proteins using weaker, possibly constitutive promoters such as GAP could 
reveal a synergistic effect.  Furthermore, any enhancement at this step may have been 
limited by similarity differences between the S. cerevisae proteins used and their P. 
pastoris homologs, particularly in the case of Snc2.  Future work in this area should 
focus on first isolating the native P. pastoris sequences.  
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Chapter 4-The Unconventional Secretion of the 
Cancer Differentiation Antigen MelanA in Pichia 
pastoris 
  
 105 
Abstract 
Protein secretion by Pichia pastoris can result in protein yields in the gL
-1
 range.  The 
tendency of P. pastoris to secrete few native proteins, coupled with a simple and well 
defined growth medium, result in high purities of recombinant protein simply by 
removing the cells by centrifugation or filtration.  As some proteins are unable to be 
successfully secreted by the traditional secretory pathway, we chose to explore the use 
of unconventional secretion to lead to the extracellular localization of the cancer 
antigen MelanA.  A plasmid was designed that would result in the production of a 
fusion protein between the unconventionally secreted protein enolase and MelanA.  A 
similar fusion was shown to lead to the extracellular localization of GFP and invertase 
in Saccharomyces cerevisae.  Shake flask cultures exhibited fusion protein in the 
culture supernatant as determined by Western blotting with anti-MelanA antibodies.  
Enolase-MelanA fusion protein was also found bound to the cell exterior and could be 
released by washing of the cells with a 0.1 M Tris buffer (pH 7.6) with 0.5% 2-
Mercaptoethanol.  High cell density fermentation failed to accumulate enolase-
MelanA fusion in the culture supernatant, but did result in protein bound to the cell 
walls.  Western blotting with anti-Candida albicans enolase indicates that degradation 
of the fusion protein is occurring in the culture supernatant, preventing accumulation.   
Introduction 
The secretion of recombinant proteins by the yeast Pichia pastoris is an attractive 
means to achieve high yield and purity of a desired target molecule.  Current methods 
to achieve secretion utilize the Saccharomyces cerevisae -mating factor signal 
sequence to direct the translocation of the target protein into the ER and the rest of the 
secretory pathway.  This fusion protein is then packaged into secretory vesicles and 
released into the extracellular environment.  For P. pastoris, secretion of recombinant 
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proteins is especially attractive considering its simple growth medium and the 
tendency of P. pastoris to secrete few native proteins.  Removal of the cells yields a 
supernatant highly enriched in the target protein of interest.  However, there are certain 
proteins that are unable to be secreted by this process.  There could be a number of 
factors at play, such as poor translation, improper folding and retention in the ER, and 
targeting to other compartments of the cell.   
 
Unconventional protein secretion is a general term used to describe the release of 
proteins to the culture supernatant by methods that circumvent the traditional ER-golgi 
secretory route (Nombela et al. 2006; Nickel and Seedorf 2008).  A number of proteins 
have been described that undergo this type of secretion, including fibroblast growth 
factor 2 (Engling et al. 2002), interleukin-1B (Andrei et al. 1999), and a variety of 
glycolytic enzymes (Chaffin 2008).  One of these glycolytic enzymes, enolase, has 
been shown to be secreted by both S. cerevisae and Candida albicans (Jong et al. 
2003; Edwards et al. 1999).  In C. albicans, enolase secretion is implicated in the 
progress of the infection by this yeast, as it promotes tissue invasion through binding 
to plasminogen and plasmin, providing C. albicans cells with a localized high 
concentration of enzymes required for the breakdown of extracellular matrix proteins 
(Jong et al. 2003).  Once secreted, enolase remains associated with the cell wall.  The 
method by which it is secreted is currently unknown.   
 
López-Villar et. al. created enolase-GFP and enolase-invertase fusions, demonstrating 
the ability of enolase to lead to the extracellular localization of other proteins (López-
Villar et al. 2006).  This study provided the impetus for the creation of fusion proteins 
between enolase and the cancer differentiation antigen MelanA.  MelanA is an 
attractive vaccine candidate for cancer immunotherapy, owing to its wide distribution 
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in various cancer types and its restricted expression in normal tissue.  Secretion of 
MelanA by the traditional -mating factor directed route has been unsuccessful, 
making this a good candidate for unconventional protein secretion directed by enolase.  
This paper will discuss the utilization of unconventional protein secretion as a new 
means to achieve extracellular localization of recombinant proteins by P. pastoris.   
Materials and Methods 
Enolase cloning 
The Eno1 gene sequence was found by a BLAST search of the P. pastoris genome 
using the S. cerevisae Eno1 sequence homolog.  Using this sequence, the gene was 
amplified from P. pastoris X33 genomic DNA that was isolated using the Yeastar 
genomic DNA kit (Zymo Research, Orange, CA).  The primers were obtained from 
Integrated DNA Technologies (Integrated DNA Technologies, Coralville, IA) and were 
designed to add a 5' BstBI site and a 3' XhoI site for cloning into pPICZ A 
(Invitrogen, Carlsbad, CA). The Eno1 PCR product was TA cloned into pCR2.1 and its 
sequence verified. A construct bearing the correct sequence and pPICZ A was 
digested with BstBI and XhoI (New England Biolabs, Ipswich, MA) and separated on 
a 1% agarose gel. Bands were purified using the MinElute Gel Extraction Kit (Qiagen, 
Valencia, CA) and fragments were ligated using the QuickLigase Kit (New England 
Biolabs, Ipswich, MA). Chemically competent TOP10 cells were transformed using a 
heat shock protocol, and transformants selected on Luria broth with 50 µg/ml Zeocin 
(Invitrogen, Carlsbad, CA). The presence of the correct insert was confirmed by 
colony PCR using primers specific to the AOX1 promoter and transcription 
terminator.  The new plasmid was termed pEZ and was used for further cloning 
experiments.  
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The MelanA gene was previously prepared for use with pPICZ A and contained a 5' 
XhoI and 3' NotI site.  A pCR2.1 construct containing MelanA and the pEZ plasmid, 
were digested with XhoI and NotI, the bands separated and purified by gel 
electrophoresis, and ligated with QuickLigase, as before.  P. pastoris KM71H 
(Invitrogen, Carlsbad, CA) was made competent using the condensed protocol (Lin-
Cereghino et al. 2005).  Briefly, a 50 ml culture of P. pastoris was grown in YPD (1% 
yeast extract, 2% peptone, 2% dextrose) to an OD600 of 0.8-1.0 and the cells collected 
by centrifugation at 500g. The pellet was resuspended in 9 ml BEDS buffer ((10 mM 
bicine-NaOH, pH 8.3, 3% (v/v) ethylene glycol, 5% (v/v) dimethyl sulfoxide, 1 M 
sorbitol) supplemented with 1 ml dithiothreitol and the cells were incubated with 
gentle shaking for 5 min. at 30°C.  The cells were again collected by centrifugation, 
and resuspended in 0.5 ml BEDS buffer without DTT.  One µg of plasmid was 
linearized by digestion with PmeI (New England Biolabs, Ipswich, MA), a 1% agarose 
gel run and stained with ethidium bromide, and the linearlized plasmid excised and 
purified with the MinElute DNA Cleanup Kit (Qiagen, Valencia, CA).  A total of 100 
ng of linearized DNA was mixed with 40 µl competent cells, incubated on ice for 5 
minutes, and subjected to electroporation using a Gene Pulser II (BioRad Laboratories, 
Hercules, CA) set to 1.5 kV, 100 µW, 25 µF.  Cells were quickly resuspended with 0.5 
ml YPD and 0.5 ml 1 M sorbitol, allowed to incubate at 30°C for 1 hour, and plated on 
YPD with 1 M sorbitol and 100 µg/ml zeocin (Invitrogen, Carlsbad, CA).  
Transformants were screened for the presence of the insert using colony PCR as 
described before. 
Expression Studies 
P. pastoris strains expressing Enolase-MelanA were grown in 5 ml YPD overnight at 
30°C.  The cultures were diluted in 10 ml YPD to an OD600 of 0.2 and allowed to grow 
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up to an OD of 1 before being collected by centrifugation.  The pellets were 
resuspended in 10 ml BMM (100 mM potassium phosphate pH 6.0, 1.34% (w/v) yeast 
nitrogen base, 4x10
-5
% (w/v) biotin, 0.5% (v/v) methanol) or BMMY (BMM + 1% 
(w/v) yeast extract and 2% (w/v) peptone) and allowed to grow at 25°C for up to 96 
hours.  Every 24 hours, a one ml sample was taken to determine OD600 and the cells 
were collected by centrifugation.   
Protein Methods 
Supernatants were filtered through a 0.2 µm Acrodisc
TM
 syringe filter (Pall, East Hills, 
NY) and diluted with 4X LDS sample buffer (Invitrogen, Carlsbad, CA) and 5% 2-
mercaptoethanol, followed by heating at 65°C for 10 minutes, to prepare the samples 
for SDS-PAGE.  The cells were frozen at -20C until the cultures were terminated, at 
which point the pellets from each time point were lysed using yeast breaking buffer 
(50 mM sodium phosphate buffer pH 7.4, 1 mM PMSF, 1 mM EDTA, 5% glycerol) 
and acid-washed glass beads as recommended by the manufacturer (Invitrogen, 
Carlsbad, CA).  The lysate was centrifuged and the intracellular soluble material 
removed and prepared for SDS-PAGE.  The remaining insoluble lysate was gently 
resuspended with yeast breaking buffer containing 1% SDS, and this material was 
prepared for SDS-PAGE as well. 
 
A ten µl aliquot of each gel sample was loaded onto precast bis-tris gels (Invitrogen) 
and run in MES buffer for 40 minutes at 200V.  Gels were stained with SimplyBlue 
Safe Stain (Invitrogen), or blotted to nitrocellulose membranes (Sambrook 2001).  
Immunoblotting was carried out using the WesternBreeze kit (Invitrogen, Carlsbad, 
CA).  The primary antibodies were a monoclonal anti-MelanA antibody or a 
polyclonal anti-C. albicans-Enolase antibody (Takara Bio USA).   
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Extraction of cell associated protein was performed by resuspending cell pellets in pH 
7.6 or 9.0 tris buffer supplemented with 0.5% 2-mercaptoethanol or 10 mM DTT.  The 
samples were incubated at 37°C for 15 min before the cells were pelleted and the 
supernatants taken for further analysis. 
Fermentation 
P. pastoris clones exhibiting fusion protein production were chosen for scale up to a 
2.5 L fermentation.  Briefly, a 50 ml YPD culture of each strain was grown to an 
OD600 of 8-10 and used to inoculate a 2.5 L working volume New Brunswick BioFlo 
Figure 4-1-An alignment of the P. pastoris, C. albicans, and S. cerevisae Eno1 
homologs. 
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3000 fermenter (New Brunswick Scientific Co., Edison, NJ) containing 1 L of 
modified basal salts medium (0.23 g·L
-1
 CaSO4-2H2O, 4.55 g·L
-1
 K2SO4, 3.73 g·L
-1
 
MgSO4-7H2O, 10.3 g·L
-1
 KOH, 6.68 ml·L
-1
 H3PO4, 5% (v/v) glycerol) with 0.5 ml 
Antifoam 204 (Sigma, St. Louis, MO).  The addition of 15% (v/v) ammonium 
hydroxide was used to maintain the pH at 6.0 and also to serve as the nitrogen source.  
Dissolved oxygen (DO) was controlled at 40% with a combination of increasing 
agitation and pure oxygen supplementation.  After glycerol consumption during the 
batch phase, marked by a sharp increase in dissolved oxygen, methanol feeding was 
initiated using a closed-loop proportional, integral, derivative (PID) control scheme to 
maintain the methanol level at 1.0 g·L
-1 
(Damasceno et al. 2004).  Samples were taken 
periodically to determine OD600 and wet cell weight, as well as to collect supernatant 
and insoluble and soluble cell extracts.  
Results 
Enolase Cloning 
The sequence for the P. pastoris enolase gene was provided by Dr. James Cregg, and 
this sequence was used to design primers to amplify the gene from P. pastoris genomic 
DNA.  DNA sequencing confirmed the identity of the sequence, and an alignment of 
the P. pastoris, S. cerevisae, and C. albicans Eno1 protein products can be seen in 
Figure 4-1, showing the highly conserved sequence of the enzyme.  The primers were 
designed to add a 5' BstBI site and a 3' XhoI site for cloning into pPICZ A.  Digesting 
pPICZ A with these enzymes removes the -mating factor secretion signal.   
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Purified enolase and pPICZ A DNA fragments digested with BstBI and XhoI were 
religated to generate the plasmid pEZ (Figure 4-2).  In this construct, the multiple 
cloning site from pPICZ A is maintained, allowing the insertion of genes at the XhoI 
and NotI sites.  Cloning of genes using these restriction enzymes in pPICZ A 
generates a fusion protein between the -mating factor and the protein of interest, and 
this capability was maintained in pEZ.  The cancer differentiation antigen MelanA was 
cloned into pEZ using XhoI and NotI, generating an enolase-MelanA fusion product.  
This construct was transformed into P. pastoris KM71H, and transformants were 
selected by zeocin resistance. 
 
Figure 4-2-The enolase gene and pPICZ A were digested with 
BstBI and XhoI and the fragments purified by gel extraction.  
Religation generated the plasmid pEZ, in which the full length 
enolase takes the place of the -mating factor secretion signal. 
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Small Scale Expression Studies 
Three transformants (designated EnoMel1, EnoMel2, or EnoMel3) were picked and 
grown in 10 ml BMM shake flask cultures to look for fusion protein secretion.  When 
compared with a control KM71H culture, all clones had similar growth rates.  The 
culture supernatant for each clone contained fusion protein at the expected size of ~60 
kDa when probed with anti-MelanA antibodies (Figure 4-3, Lanes 1, 3, and 5).  
Furthermore, each culture also contained enolase-MelanA bound to the cell walls and 
extracted by washing with 2 mM Tris (pH 8.0) with 0.5% 2-mercaptoethanol (Figure 
4-3, Lanes 2, 4, and 6).  There was no degradation seen in any of the cultures, and no 
apparent differences in protein yield in the supernatant.  Clone EnoMel3, however, did 
 
Figure 4-3-Three P. pastoris clones expressing 
the enolase-MelanA fusion protein were grown 
in shake flask cultures in BMM (pH 6.0).  
Their supernatants were collected and the cell 
pellet washed to remove cell wall-bound 
protein.  Lanes 1, 3, and 5-Supernatant 
samples.  2, 4, and 6-Cell wash samples. 
MelanA 
Control 
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seem to yield more protein that was extractable from the cell surface (Figure 4-3, Lane 
6), and this clone was selected for future experiments. 
 
Next we decided to test the effects of medium composition and pH on protein yield.  
Cultures were prepared with either BMM or BMMY at either pH 3.0 or 6.0, and 
maintained at 25°C for 48 hours.  In each of the four conditions tested, enolase-
MelanA was seen in Western blots at 24 and 48 hours (Figure 4-4).  A band was 
detected migrating at a higher molecular weight, which could correspond to 
dimerization of the fusion protein.  At 48 hours, however, only the culture with BMM 
at pH 6.0 had an increase in enolase-MelanA yield.  All other conditions tested 
resulted in a loss of protein over time, presumably due to proteolysis.  When the cells 
 
Figure 4-4-P. pastoris EnoMel3 was grown under 
four different conditions and the supernatants from 
24 and 48 hours examined by immunoblotting with 
anti-MelanA antibodies.  M-Protein ladder.  +-
MelanA control.  1-BMMY pH 3.0.  2-BMMY pH 
6.0.  3-BMM pH 3.0.  4-BMM pH 6.0. 
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were washed with 2 mM tris pH 8.0/0.5% 2-mercaptoethanol only the cell pellet from 
BMM pH 6.0 had any anti-MelanA reactive protein (Figure 4-5, B), and this wash 
fraction had the lowest amount of contaminating host protein (Figure 4-5, A).  From 
these results, minimal medium at pH 6.0 was chosen for all future experiments. 
Release of Cell Wall Bound Protein 
The effect of temperature and different cell washing conditions on enolase-MelanA 
yield was also tested.  Cell pellets were collected and normalized for culture OD600 at 
48 hr post induction from cultures maintained at 20°C or 30°C, and washed with one 
 
Figure 4-5- P. pastoris EnoMel3 was grown in either BMM or 
BMMY at pH 3.0 or 6.0. Cell pellets after 24 or 48 hr of induction 
were washed with 2 mM Tris pH 8.0 with 0.5% 2-mercaptoethanol.  
Proteins released from the cell walls were analyzed by SDS-PAGE 
gels and Western blotting.   A-Coomassie stained SDS-PAGE.  B-
Immunoblot with anti-MelanA antibodies.  M-Protein ladder.  +-
MelanA control.  1-BMMY pH 3.0.  2-BMMY pH 6.0.  3-BMM pH 
3.0.  4-BMM pH 6.0. 
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of four buffers: 0.1 M Tris (pH 7.6) with 0.5% 2-Mercaptoethanol; 0.1 M Tris (pH 7.6) 
with 10 mM DTT; 0.1 M Tris (pH 9.0) with 0.5% 2-Mercaptoethanol; or 0.1 M Tris 
(pH 9.0) with 10 mM DTT.  The pH 9.0 buffers, regardless of reducing agent, released 
more total protein as determined by coomassie staining of an SDS-PAGE gel (Figure 
4-6, Lanes 3 and 4).   
 
Growth at 30°C also led to higher amounts of extractable total protein.  While a 
reducing agent is necessary for enolase-MelanA release, the choice of DTT or 2-
Mercaptoethanol did not have any impact on protein totals.  Western blotting with 
anti-MelanA antibodies however indicates that the level of fusion protein released 
from approximately the same number of cells was nearly the same regardless of 
washing conditions used (Figure 4-6, right). 
 
Figure 4-6-Cell pellets from P. pastoris EnoMel3 cultures grown in BMM pH 
6.0 at either 20 or 30°C were normalized for cell number and washed with one of 
four buffers to test their effects on fusion protein release from the cell surface.  
Duplicate gels were stained with coomassie (left) or transferred to nitrocellulose 
membranes and blotted with anti-MelanA antibodies (right).  +-MelanA control.  
M-Protein ladder.  1-0.1 M Tris pH 7.6 + 0.5% 2-Mercaptoethanol.  2-0.1 M Tris 
pH 7.6 + 10 mM DTT.  3-0.1 M Tris pH 9.0 + 0.5% 2-Mercaptoethanol.  4-0.1 
M Tris pH 9.0 + 10 mM DTT. 
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High Cell Density Fermentation 
Based on results obtained at the small scale, a fermentation was prepared using the ¼ 
basal salts medium that has been used successfully for high protein yields of a 
traditionally secreted protein, the A33 scFv (Damasceno et al. 2004).  Enolase-MelanA 
was undetectable in the supernatant by immunoblotting, and the amount washed from 
the cell wall was also very low (data not shown).   
 
Standard P. pastoris fermentations typically contain 1.34 mM CaSO4, however 
calcium concentration has been shown to be an important factor for multivesicular 
body fusion with the plasma membrane (Savina et al. 2005), a possible route for 
 
Figure 4-7-A P. pastoris EnoMel3 high cell density fermentation of with 
basal salts media at pH 6.0 was carried out, and the supernatants and 
cell pellets examined for the presence of enolase-MelanA fusion protein 
by coomassie staining (left) and immunoblotting with anti-MelanA 
antibodies (right).  Cell pellets were washed with 0.1 M Tris (pH 7.6) + 
0.5% 2-Mercaptoethanol.  1 and 2-24 and 48 hour culture supernatants, 
respectively.  3 and 4-24 and 48 hour cell washes, respectively. 
188
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enolase export.  We chose to increase the concentration of CaSO4 four fold, to 5.34 
mM.  At 24 and 48 hr, higher calcium concentrations did increase fusion protein 
released from the cell wall (Figure 4-7, Lanes 3 and 4), but at these time points 
nothing was detected in the supernatant (Figure 4-7, Lanes 1 and 2).  Fusion was 
found in the supernatant at 72 and 96 hours (Figure 4-8, Lanes 3 and 4).  Western 
blotting with a polyclonal antibody raised against C. albicans Eno1 showed degraded 
forms of the fusion protein in the supernatant at all time points, with the degradation 
becoming more extensive at 72 and 96 hours (Figure 4-8).  The primary band seen 
with the anti-enolase antibody does migrate lower than the fusion protein, at 
approximately ~50 kDa.  This band could possibly be enolase itself, which has a 
molecular weight of ~47 kDa.   
 
One ml fermentation samples were taken and protein extracted from the cell surface as 
with the shake flask cultures.  A further goal of this experiment was to determine if 
starvation and/or temperature upshift led to an increase in extractable enolase-MelanA 
from the cell surface, as has been seen with glyceraldehyde-3-phosphate 
dehydrogenase (Delgado et al. 2003).  Extraction of a pellet with no treatment yielded 
1.17 mg/ml of total protein, while incubation of the pellet in prewarmed water at 30°C 
for one hr increased the level of extractable total protein to 1.69 mg/ml (Figure 4-9, 
A).  Incubation of the pellet in water at 37°C resulted in no change.  Incubation in 
YPDS at either 30 or 37°C for one hour decreased the extractable total protein 
concentration by 19.5 and 14.6 fold, respectively.  This difference in total protein can 
be seen in SDS-PAGE (Figure 4-9, B, Lanes 3 and 5), as 7 µl of protein extract was 
loaded per lane, regardless of protein concentration.  The difference in enolase-
MelanA fusion yields as determined by immunoblotting is negligible for all treatments 
except 37°C YPDS (Figure 4-9,C, Lane 5), which exhibited a noticeable loss in band 
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intensity.  No fusion protein was found in the water or YPDS used for incubation 
(Figure 4-9, C, Lanes 6-9).  The percentage of enolase-MelanA in these samples is 
very low, as no protein band can be seen in coomassie staining that corresponds to the 
immunoblot.   
Discussion 
The secretion of heterologous proteins by the traditional secretory pathway is a well-
established method to aid in downstream purification.  As we and others have seen, 
heterologous proteins are often unable to be properly folded and secreted in yeast 
systems (Agaphonov et al. 2002, 2005; Sagt et al. 2002).  To try and circumvent the 
quality control checkpoints within the secretory pathway preventing secretion, we 
generated a fusion utilizing a protein that is secreted in a manner that bypasses the ER 
 
Figure 4-8- A P. pastoris EnoMel3 high cell density fermentation with basal salts 
media at pH 6.0 was carried out, and the supernatants and cell pellets examined 
for the presence of enolase-MelanA fusion protein by immunoblotting with anti-
MelanA antibodies (Left) or anti-C. albicans enolase antibodies (Right).  One ml 
cell pellets were washed with one ml of 0.1 M Tris (pH 7.6) + 0.5% 2-
Mercaptoethanol.  All times are post methanol induction.  +-MelanA control.  M-
Protein ladder.  1 and 5-24 hours.  2 and 6-48 hours.  3 and 7-72 hours.  4 and 
8-96 hours. 
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altogether.   
 
Unconventional protein secretion has only recently been reported, with the secretion 
routes for proteins such as fibroblast growth factor 2 and interleukin  1 being the 
most well characterized (Engling et al. 2002; Andrei et al. 1999).  In yeast, however, 
only one protein is known to be secreted by an unconventional route, the yeast a-
factor.  Yeast a-factor is a 12 amino acid peptide that is transported across the 
membrane by Ste6, a member of the ATP-binding cassette transporters (McGrath and 
Varshavsky 1989).  Evidence for the secretion of other soluble proteins through 
unconventional methods is mounting and the pathways are being elucidated. 
 
One unconventionally secreted protein found in a number of organisms is enolase.  
Fusions between enolase and either invertase or GFP results in the extracellular 
localization of the fusion protein in S. cerevisae (López-Villar et al. 2006).  We chose 
to explore the possibility of using enolase to direct the extracellular localization of 
cancer antigens resistant to secretion by the traditional pathway in P. pastoris.  The 
plasmids designed in this study were prepared so that the full length enolase gene 
would replace the -mating factor secretion signal.  The result is a fusion protein 
between enolase and the cancer differentiation antigen MelanA, with a Kex2 protease 
site and short linker between them.  Unlike with -mating factor directed secretion, 
the fusion protein should not be cleaved by Kex2 protease, as its secretion should 
completely bypass the traditional secretion pathway.  The P. pastoris enolase sequence 
shares high homology between the S. cerevisae and C. albicans proteins, and fusion 
proteins between enolase and MelanA were detected in the culture supernatant by 
immunoblotting.  At the small scale, the absence of host proteins in the culture 
supernatant suggests that lysis was not responsible for the extracellular localization of 
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the fusion protein.  Culture conditions were varied in an attempt to maximize the 
amount of protein located in the supernatant and on the cell exterior, and we 
determined that the optimal yields were achieved minimal medium at pH 6.0.  The use 
of pH 3.0, at which P. pastoris grows well and exhibits low proteolytic activity in the 
culture supernatant, had undetectable levels of the fusion protein bound to the cell 
wall, and the amount in the supernatant decreased from 24-48 hours.   
 
Shake flask culture results indicate that the majority of the fusion protein remains 
associated with the cell pellet.  This protein can be released by incubating the cells in 
buffers containing reducing agents.  Interestingly, the pH of the buffer or the type of 
reducing agent, either DTT or 2-mercaptoethanol, did not result in any appreciable 
differences in fusion protein released from the cell pellet.  These conditions did greatly 
impact the amount of other host proteins released from the cell.  The pH 9.0 extracts 
yielded far more protein than did the pH 7.6 buffers.  This is likely due to the release 
of protein bound by ionic interactions with negatively charged cell wall glycoproteins, 
as many yeast proteins have a pKa <8.0 (Klis et al. 2007).  Despite the wide 
differences in total protein yields, there was little difference in enolase-MelanA 
released by the different buffers.  This suggests that the interaction of the fusion 
protein with the cell wall is likely though disulfide bond formation, as the presence of 
a reducing agent is the critical component in enolase-MelanA release.  Since pH 7.6 
Tris buffer with 2-mercaptoethanol yields the same amount of fusion protein with the 
lowest level of contaminating host protein, this was the buffer chosen for all 
subsequent experiments.   
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It should be noted that washing cell pellets with a high pH buffer containing 2-
mercaptoethanol can lead to perturbation of the plasma membrane (Klis et al. 2007).  
This work speculated that this perturbation could be responsible for the apparent 
location of traditionally cytoplasmic proteins at the cell surface.  Since enolase and 
other putative unconventionally secreted proteins are highly enriched in the cytoplasm, 
Klis et al. suggest that even a small amount of cell lysis would lead to a noticeable 
increase of these proteins at the cell exterior.  With enolase-MelanA, however, this 
explanation seems to be unlikely.  Intracellular lysates from these cells exhibit very 
high levels of fusion protein seen by Western blotting (data not shown).  If the pH 9.0 
 
Figure 4-9-One ml samples from a P. pastoris EnoMel3 fermentation were 
harvested and the cells pelleted by centrifugation.  The pellets were 
resuspended in either sterile water or YPDS prewarmed to 30 or 37°C and 
incubated at the same temperatures for one hour.  The cells were then again 
pelleted and the cell associated protein extracted by incubation with 0.1 M Tris 
(pH 7.6) with 0.5% 2-mercaptoethanol for 30 minutes.  A.  The protein 
concentrations for the various treatments were determined by Bradford assay.  
B and C- Samples of the extracted protein and the water or YPDS used in the 
incubation were run on SDS-PAGE (B) and analyzed by immunoblotting with 
anti-MelanA antibodies (C).  L-Molecular weight marker.  1-No treatment.  2-
30°C water/extraction.  3-30°C YPDS/extraction.  4-37°C water/extraction.  5-
37°C YPDS/extraction.  6-30°C water.  7-30°C YPDS.  8-37°C water.  9-37°C 
YPDS. 
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buffers did indeed lead to release of protein from the cytoplasm, it follows that the 
level of enolase-MelanA fusion in these extractions would increase in relation to the 
amount released by the pH 7.6 buffers.  Enolase-MelanA levels seen in the pH 9.0 
wash do not increase, indicating that the increase in total protein is due to the release 
of ionically bound protein from the cell wall under these conditions. 
 
High cell density fermentation of P. pastoris is an effective way to greatly enhance the 
amount of recombinant protein produced by this organism.  For traditionally secreted 
proteins, fermentation can result in protein concentrations in the gram per liter range.  
With enolase-MelanA, initial fermentations failed to yield protein in the culture 
supernatant as was seen in shake flask cultures.  Furthermore, washing of the cell 
pellets failed to release any fusion protein.  Elevating the CaSO4 concentration of the 
media yielded enolase-MelanA in the supernatant at 72 and 96 hours, and throughout 
fermentation bound to the cell mass.  Blotting with anti-enolase polyclonal antibodies 
indicates that degradation of the fusion protein occurs heavily at 72 and 96 hours.   
 
There are a number of factors in P. pastoris fermentation that can lead to high levels of 
degradation.  As growth of P. pastoris on methanol has been shown to be very 
stressful, with up to 20% cell death being seen shortly after induction (Hohenblum et 
al. 2003), increased protease activity in the culture supernatant is the likely cause of 
enolase-MelanA degradation.  Compounding the increased amount of proteases, 
studies of proteolytic activity in P. pastoris supernatants have shown that at pH 6.0 
where enolase-MelanA secretion is maximized in shake flasks, protease activity is 
very high (Shi et al. 2003).  Higher salt concentrations in P. pastoris fermentations 
have been shown to result in a lipid like substance in the culture supernatant that can 
interfere with protein purification (Brady et al. 2001).  Brady et al. speculated that this 
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was due to cell lysis.  The amount of cell lysis late in fermentation and the resulting 
increase is proteolytic activity could be quickly degrading any fusion protein located 
in the culture supernatant.  The lower yield of extracted protein from cell pellets 
incubated in YPDS for one hour is interesting, especially since there is no appreciable 
difference in the amount of enolase-MelanA fusion.  YPDS incubation for one hr 
specifically results in lower levels of contaminating host protein in the final extraction.  
It is possible that incubation in YPDS allows the cells to continue to grow and remodel 
their cell walls such that there is less protein available for extraction, however more 
work needs to be done to study this phenomenon. 
 
Ultimately, the yields achieved in this work are very low, and releasing protein from 
the cell mass results in the concurrent release of a number of P. pastoris host proteins.  
As the primary goal of protein secretion is to increase initial purity prior to 
downstream purification, these results suggest that enolase driven secretion is not 
effective for industrial scale protein production.  Furthermore, cleavage of enolase and 
the target protein must occur.  The inclusion of specific protease sites between the two 
proteins could be an effective means to achieve this, but this type of processing is 
expensive and difficult to implement at an industrial scale.  Future work elucidating 
the precise mechanism of enolase export might provide insight that could increase the 
yield of secreted fusion protein.  For example, it has been shown that certain mutations 
of S. cerevisae can lead to the increased export of enolase to the culture supernatant 
(Kim and Park 2004), something that might also be possible with P. pastoris.  Simple 
methods to separate enolase from the protein of interest also must be developed.  
However, in certain cases where intracellular expression and traditional secretion 
proves ineffective, unconventional secretion could provide an additional method to 
achieve protein for further studies. 
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Pichia pastoris is proving to be a capable alternative to bacterial and mammalian 
expression platforms.  This work has described the use of P. pastoris to produce a 
clinically useful protein, NY-ESO-1.  Using purification methods originally designed 
for Escherichia coli, protein expressed in an intracellular insoluble fraction was able to 
be collected and solubilized, however the protein exhibited the loss of the C-terminal 
6X his tag.  The loss of the his tag was shown to be due to the presence of a Kex2 
protease site directly upstream of the feature, and the removal of this cleavage signal 
resulted in the maintenance of the his tag on the final protein.  The secretory pathway 
capacity was enhanced by cooverexpressing the Saccharomyces cerevisae SNARE 
protein Sso1, which led to the improvement of secretion of the single chain antibody 
fragment against A33.  Cooverexpression of the S. cerevisae SNARE protein Snc2, 
however, did not lead to an enhancement in yields, highlighting the importance of 
SNARE protein sequence homology in driving successful fusion events.  Finally, an 
attempt was made to secrete another clinically interesting protein, MelanA, through an 
unconventional secretory route.  In shake flasks it appears that the fusion protein does 
escape to the extracellular space, in particular becoming bound to the cell walls.  In 
fermentor culture, however, fusion protein is only detected in the supernatant at very 
late time points, possibly as a result of cell lysis.  In addition to the work described in 
this manuscript, there are numerous other exciting and innovative research projects 
that aim to expand the capabilities of this interesting organism.   
 
One well developed project with great potential is the humanization of the P. pastoris 
glycosylation pathway.  Proper glycosylation of recombinant proteins is important to 
ensure proper protein activity and stability (Helenius and Aebi 2001), but also to limit 
the potential for adverse immune responses caused by non-native carbohydrate 
structures.  The importance of proper glycosylation is one of the primary reasons 
 131 
mammalian cell culture systems are so heavily used, despite their limitations.  The 
first step in achieving humanized glycosylation was to remove the ability to 
hypermannosylate glycoproteins.  A strain of P. pastoris that is fully humanized has 
been developed that required the removal of four genes with the subsequent 
introduction of 14 heterologous genes (Hamilton et al. 2006).  A recombinant 
erythropoietin was generated in these strains with activity similar to that produced in 
mammalian cell culture systems.  Also in this system, different glycoforms of IgG 
have been produced that vary in their ability to mediate immune function.  This system 
has the potential to supplant mammalian cells as the workhorse for therapeutic protein 
production.   
 
Another active area of research is the cooverexpression of chaperones in P. pastoris.  
Work in our lab has shown the effectiveness of overexpressing BiP in addition to A33 
scFv to enhance yields of secreted protein three fold (Damasceno et al. 2007).  Inan et 
al improved the secretory yields of Necator americanus secretory protein (Na-ASP1), 
which contains 20 cysteine residues, by the cooverexpression of protein disulfide 
isomerase (Inan et al. 2006).  Zhang et al. demonstrated that secretory yields of 
granulocyte colony stimulating factor could be improved not only by the co-
overexpression of BiP or PDI, but also by the co-overexpression of the cytosolic 
chaperones Ssa1p and YDJ1p from S. cerevisae (Zhang et al.).  In this case, the 
overexpression of cytosolic chaperones is thought to stabilize the unfolded 
intermediate protein prior to its import into the ER.  A library of P. pastoris clones 
harboring various combinations of ER and cytosolic chaperones could be constructed 
to quickly screen for their effectiveness at improving secretory yields of each new 
target protein. 
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The AOX1 promoter is by far the most commonly used promoter for heterologous 
protein expression in P. pastoris.  Hartner et al. recently fully characterized a library of 
AOX1 promoter variants with activities that range between 6% and 160% of wild type 
(Hartner et al. 2008).  They were also able to generate AOX1 promoter fragments that 
were tightly repressed by glycerol, but were strongly activated either by starvation 
conditions or other carbon sources.  This is in contrast with the wild type promoter, 
where the presence of methanol is necessary for strong induction.  This library of 
promoters will provide researchers a toolbox to fine tune the strength of induction to 
maximize protein yields, while also providing a means for inducing other accessory 
proteins, such as chaperones, at low levels.   
 
The use of P. pastoris for high level recombinant protein production will continue to 
improve in popularity.  The advantages it offers over other well established production 
systems are many.  The construction of stable expressing strains is straightforward, the 
growth is rapid and occurs to very high cell densities, and most importantly it can 
successfully modify and secrete many heterologous proteins.  With the recent public 
release of the P. pastoris genome, there now exists even greater potential to rationally 
design strains optimized for expression of a wide array of proteins.  P. pastoris is 
poised to make significant contributions to recombinant protein expression in the 
future. 
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